

(19) **DANMARK**

(10) **DK/EP 3589728 T3**



Patent- og  
Varemærkestyrelsen

(12) Oversættelse af  
europæisk patentskrift

- 
- (51) Int.Cl.: **C 12 N 5/0783 (2010.01)** **C 12 N 5/0789 (2010.01)**
- (45) Oversættelsen bekendtgjort den: **2022-09-19**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2022-09-07**
- (86) Europæisk ansøgning nr.: **18710125.8**
- (86) Europæisk indleveringsdag: **2018-03-02**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-01-08**
- (86) International ansøgning nr.: **GB2018050542**
- (87) Internationalt publikationsnr.: **WO2018158587**
- (30) Prioritet: **2017-03-03 GB 201703476**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Imperial College Innovations Limited, Level 1 Faculty Building, c/o Imperial College, Exhibition Road, London SW7 2AZ, Storbritannien**
- (72) Opfinder: **BRADY, Hugh J.M., Imperial College London, South Kensington Campus, Exhibition Road, London, Greater London SW7 2AZ, Storbritannien**  
**FUCHTER, Matthew, Imperial College London, South Kensington Campus, Exhibition Road, London, Greater London SW7 2AZ, Storbritannien**
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Naturlige dræberceller**
- (56) Fremdragne publikationer:  
**US-A1- 2007 048 290**  
**KHATUNA GAGNIDZE ET AL: "Nuclear receptor REV-ERB[alpha] mediates circadian sensitivity to mortality in murine vesicular stomatitis virus-induced encephalitis", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 113, no. 20, 3 May 2016 (2016-05-03), pages 5730-5735, XP055421217, US ISSN: 0027-8424, DOI: 10.1073/pnas.1520489113**  
**DOUGLAS KOJETIN ET AL: "Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB", ACS CHEMICAL BIOLOGY, vol. 6, no. 2, 18 February 2011 (2011-02-18), pages 131-134, XP055100259, ISSN: 1554-8929, DOI: 10.1021/cb1002575**  
**SUKUMARAN S ET AL: "Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 62, no. 9-10, 31 July 2010 (2010-07-31), pages 904-917, XP027212615, ISSN: 0169-409X [retrieved on 2010-06-11]**  
**C. SEILLET ET AL: "Differential Requirement for Nfil3 during NK Cell Development", THE JOURNAL OF IMMUNOLOGY, vol. 192, no. 6, 14 February 2014 (2014-02-14), pages 2667-2676, XP055466140, US ISSN: 0022-1767, DOI: 10.4049/jimmunol.1302605**

Fortsættes ...



# DESCRIPTION

## FIELD OF THE INVENTION

**[0001]** This invention relates to expanded Natural Killer (NK) cell populations, and to methods of producing the same. Therapeutic applications are also described. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.

## BACKGROUND OF THE INVENTION

**[0002]** There has been an increase in interest in Natural Killer (NK) cells as they are cytotoxic against cancerous, pathogen-infected and otherwise damaged cells. NK cells are innate lymphoid cells (ILCs), specifically large granular cytotoxic lymphocytes that bridge the innate and the adaptive arms of the immune response. They make up 10-15% of circulating lymphocytes in the peripheral blood. NK cells also exhibit the highest level of cytotoxic activity within the immune system. Therefore, altered NK cell functionality or numbers impact the functioning of the immune system against infection and cancer. For example, a large scale study in Japan has shown that reduced levels of NK cells in a cohort of people aged over 40 is associated with a significantly higher incidence of cancer.

**[0003]** Similarly to B cells and T cells, these NK cells are derived from Common Lymphoid Progenitor (CLP) cells that in turn come from Haematopoietic Stem Cells (HSCs). However, NK cells are different from B and T cells as they lack specific cell surface antigen receptors. Due to this, NK cells may kill cancerous and pathogen-infected cells without prior sensitisation, making them part of the innate immune response. They also have a critical role in tumour immunosurveillance by directly influencing the adaptive immune response.

**[0004]** Activation of NK cells triggers them to release perforin and cytoplasmic granules containing granzymes. Perforin polymerises to form pores on target cells in the presence of  $\text{Ca}^{2+}$ . Granzymes may enter these pores into target cells, causing DNA fragmentation and apoptosis. NK cells may also secrete cytokines, which trigger the action of other immune cells in the adaptive arm of the immunity.

**[0005]** Due to the importance of NK cells in immune response against pathogen infection and cancer cells, multiple clinical trials have tested the efficacy of NK cells in adoptive transfer protocols. In adoptive transfer, NK cells isolated from the blood of donors are expanded *ex vivo* and matured into healthy and functional NK cells prior to transfusion into recipients. However, to be effective it is crucial that NK cell donors are screened for their KIR genotype, where the donor must have the appropriate KIR allelic polymorphism to the recipient to allow recognition of target cells for destruction. In any event, studies have found that the expanded

products have lower clinical success rate than expected, with less ability to kill cancerous or infected cells. Thus, there are significant barriers to the current adoptive transfer protocols.

**[0006]** An alternative therapeutic approach is to increase the number of endogenous NK cells. One method is the administration of cytokines that are essential for NK cell development. Administration of IL-2 and IL-15 was predicted to enhance NK cell development. IL-2 promotes the proliferation and cytotoxicity of NK cells, whereas IL-15 promotes the development and expansion of NK cells. However, in *in vivo* studies, the cytokines were found only stimulate a minimal expansion of NK cells with reduced half-life, even at a very high dose. Further, administered cytokines often leads to systemic toxicity due to inappropriate activation of immune responses and the induction of NK cell apoptosis.

**[0007]** Thus, using conventional methods and techniques, producing large numbers of NK cells is difficult, and producing fully functional NK cells with high cytotoxicity is even harder. There is currently no drug available that selectively increases NK cell numbers. Therefore, there is a need to develop new methods of NK cell production; both *ex vivo* to produce large numbers of functional NK cells for therapeutic and research use; and *in vivo*.

## SUMMARY OF THE INVENTION

**[0008]** Natural Killer (NK) cells have a critical role in the immune system where they destroy cancerous, pathogen-infected or damaged cells. Boosting NK cell number or functionality is predicted to increase the killing of these cells. Existing therapies such as NK cell adoptive transfer and cytokine enhancement of endogenous NK cells are not very successful in terms of their efficacy.

**[0009]** NK cells are differentiated from the HSCs in the bone marrow and distributed throughout lymphoid and non-lymphoid tissues including lymph nodes, spleen, peripheral blood, lungs and liver. Specific cytokines and transcription factors are needed to encourage HSCs to develop into NK cells. Each cytokine and transcription factor must be present at a precise time and concentration in order to push differentiation from HSCs into NK cells. However, the precise hierarchy of cytokines and transcription factors governing NK cell maturation is still incompletely understood.

**[0010]** The present inventors have worked to identify drugs that can increase NK cell number. In particular, the present inventors have focussed on E4 binding protein 4 (E4bp4), which is also known as Nfil3. Upregulation of E4bp4 is a promising strategy to increase the production of NK cells as over expression of E4bp4 in HSCs greatly enhances *in vitro* NK cell production. However, transcription factors can be hard to drug because of their structure and function. For example, they usually lack enzymatic activity or cofactor binding sites. The present inventors have shown for the first time that inhibiting the action of REV-ERB increases NK cell production. In more details the inventors have found that inhibiting the action of REV-ERB increases E4bp4 expression, which in turn increases NK cell production. In particular, the

present inventors have shown that an REV-ERB antagonist, SR8278, increases E4bp4 expression and hence NK cell production.

**[0011]** Accordingly, the present invention provides an *ex vivo* method for expanding an NK cell population, comprising the steps of: a) culturing an haematopoietic progenitor cell (HPC) comprising sample obtained from a patient; b) contacting said sample with a compound which inhibits the action of REV-ERB; and c) expanding said cells *in vitro* to produce an NK cell population.

**[0012]** Said compound may increase E4bp4 expression by decreasing REV-ERB activity. Typically said compound decreases the activity of REV-ERB- $\alpha$  and/or REV-ERB- $\beta$ . Preferably said compound decreases the activity of REV-ERB- $\alpha$  and REV-ERB- $\beta$ . In some embodiments, said compound is a REV-ERB antagonist, preferably an antagonist of REV-ERB- $\alpha$  and REV-ERB- $\beta$ . Said compound may be selected from a small molecule, a PROTAC reagent, a double stranded RNA (dsRNA), a small interfering RNA (siRNA), a small hairpin RNA (shRNA), a micro RNA, an antisense RNA, an aptamer, an antibody, a ribozyme, a peptide or a peptidomimetic. In some preferred embodiments, said compound is a small molecule, for example SR8278, ARN5187, ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine or 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine, SR8278 is particularly preferred.

**[0013]** The sample of HPCs may be obtained from bone marrow, cord blood and/or peripheral blood. In some embodiments, the compound is added within 2 days of isolating the HPCs in the sample.

**[0014]** Also described is an expanded NK cell population obtained by the method of the invention, wherein at least 90% of the NK cells are CD56<sup>+</sup> and CD45<sup>+</sup>, as well as a composition comprising an expanded NK cell population of the invention and a pharmaceutically acceptable carrier, diluent and/or excipient.

**[0015]** Also described is a compound which inhibits the action of REV-ERB for use in a method of therapy by increasing production of natural killer (NK) cells in a patient. Typically said compound is a compound of the invention as defined herein. The method of therapy may be a method of treating a disease or disorder selected from cancer, an infectious disease (acute or chronic), an autoimmune disease or a disease or disorder related to female infertility or pregnancy. The infection to be treated may be a viral infection, a bacterial infection, a protest infection, a fungal infection and/or a helminth infection. In some embodiments, the compound for use of the invention is used in combination with antibody-mediated immunotherapy. Said compound may be for administration before, simultaneously with, or after administration of the antibody-mediated immunotherapy. In some preferred embodiments, said compound is SR8278, ARN5187, ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-

carboxylate, 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine or 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine, with SR8278 being particularly preferred.

**[0016]** Described herein is also a method of treatment by increasing the number of NK cells in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound which inhibits the action of REV-ERB. Said compound may be used in combination with antibody-mediated immunotherapy.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0017]**

**Figure 1:** NK cell developmental pathway. NK cells are differentiated from Hematopoietic Stem Cells (HSCs). NK cells develop from HSC into Common Lymphoid Progenitor (CLP) cells, NK progenitor (NKP) cells, immature NK (iNK) cells, mature NK (mNK) cells and finally into conventional NK (cNK) cells, which circulate in the bloodstream. Below the diagram of the pathway are the cytokines and transcription factors that are required for NK cell development. IL-15 is one of the main cytokine required for the development of NK cells. Others are transcription factors required for the transitions shown on the diagram.

**Figure 2:** Timeline of NK cell development assay. HPCs were isolated and cultured plus Flt3L, IL-7 and SCF cytokines. At Day 2, they were then transferred onto OP9 stromal cells plus or minus drug in culture medium plus the IL-15 cytokine. The media of the cultures were changed at Day 5 and the cells were harvested and analysed at Day 9.

**Figure 3:** HPCs were cultured in NK cell-producing conditions with the addition of different drug compounds at Day 2. At Day 9, percentage of NK cells was quantified using flow cytometry. (A) Graph showing relative mature mouse NK cell (NK1.1<sup>+</sup> CD3<sup>-</sup>) production for the addition of 5, 10 and 20  $\mu$ M D4476 (positive control), Remodelin and SR8278 compared to the 'No drug' control. (B) Flow cytometry gating strategy for the identification of mouse NK cells. (C) Representative flow cytometry results with percentage of NK cells shown. Results were averaged from one experiment with six repeats and the error bars represent the mean + SD. Asterisks indicate significant differences from the two annotated results (\* is  $P \leq 0.01$ ) based on Mann-Whitney test.

**Figure 4:** HPCs were cultured in NK cell-producing conditions with the addition of different concentrations of SR8278. At Day 9, percentage of NK cells was quantified using flow cytometry. (A) Graph showing relative mature mouse NK cell (NK1.1<sup>+</sup>CD3<sup>-</sup>) production for the addition of 2, 5, 10 and 20  $\mu$ M SR8278 compared to the 'No drug' control. Results were averaged from three independent experiments with biological duplicates and technical

triplicates and the error bars represent the mean + SD. Asterisks indicate significant differences from the two annotated results (\* is  $P \leq 0.05$ ; \*\*\*\* is  $P \leq 0.0001$ ) based on Mann-Whitney test. (B) Representative (exemplary) flow cytometry results with percentage of NK cells shown.

**Figure 5:** Lineage negative cells (HPCs) were cultured in NK cell-producing conditions with the addition of 5 or 10  $\mu\text{M}$  SR8278 on Day 0, 1, 2, 3 or 4. At Day 9, percentage of NK cells was quantified using flow cytometry. (A) Graph showing relative mature mouse NK cell (NK1.1+ CD3-) production when 5 and 10  $\mu\text{M}$  SR8278 were added on different days compared to the 'No drug' control. (B) Representative flow cytometry results with percentage of NK cells shown. Addition of 5  $\mu\text{M}$  SR8278 is shown on the top, whereas addition of 10  $\mu\text{M}$  SR8278 is shown on the bottom. (C) Graph shows the number of live cells when 5 and 10  $\mu\text{M}$  of SR8278 were added on different days. Results were averaged from two experiments with four repeats each and the error bars represent the mean + SD. Asterisks indicate significant differences from the two annotated results (\* is  $P \leq 0.01$ , \*\*\* is  $P \leq 0.0001$  and \*\*\*\* is  $P \leq 0.00001$ ) based on Mann-Whitney test.

**Figure 6:** HPCs were cultured in NK cell-producing conditions with the addition of different concentrations of GSK4112. At Day 9, percentage of NK cells was quantified using flow cytometry. (A) Graph showing relative mature mouse NK cell (NK1.1+ CD3-) production for the addition of 2, 5, 10 and 20  $\mu\text{M}$  GSK4112 compared to the 'No drug' control. (B) Representative flow cytometry results with percentage of NK cells shown. Results were averaged from two experiments with four repeats each and the error bars represent the mean + SD. Asterisks indicate significant differences from the two annotated results (\* is  $P \leq 0.01$  and \*\*\* is  $P \leq 0.0001$ ) based on Mann-Whitney test.

**Figure 7:** HPCs isolated from either wild type (WT), E4bp4 knockout (KO) or heterozygous (Het) mice were cultured with the addition of 5 or 10  $\mu\text{M}$  SR8278. At Day 9, percentage of NK cells was quantified using flow cytometry. Graph showing relative mature mouse NK cell (NK1.1+ CD3-) production compared to the 'No drug' control in experiments with (A) WT, (B) Het and (C) E4bp4 KO mice. (D) Representative flow cytometry results with percentage of NK cells shown for the addition of 10  $\mu\text{M}$  SR8278. Results were averaged from two experiments with four repeats each and the error bars represent the mean + SD. Asterisks indicate significant differences from the two annotated results (\* is  $P \leq 0.01$  and \*\* is  $P \leq 0.001$ ) based on Mann-Whitney test.

**Figure 8:** HPCs were cultured with or without 5  $\mu\text{M}$  SR8278 added on Day 2. At Day 3, 4 and 5, cells were harvested in order to quantify their relative cytokines expressions by RT-qPCR. The graphs show relative expression of (A) E4bp4, (B) Id2 and (C) Eomes normalized to the housekeeping gene, Hprt.

**Figure 9:** Human CD34<sup>+</sup> cells were cultured with the addition of 5  $\mu\text{M}$  SR8278 at Day 4. At Day 14 and 16, percentage of hCD56<sup>+</sup> hCD45<sup>+</sup> (markers for human NK cells) cells was quantified using flow cytometry. (A) Graph showing percentage of hCD56<sup>+</sup> hCD45<sup>+</sup> cells compared to the

'No drug' control in different conditions. (B) Flow cytometry gating strategy for identification of human NK cells. (C) Representative flow cytometry results with percentage of NK cells shown. Results were averaged from one experiments with six repeats each and the error bars represent the mean + SD.

**Figure 10:** (A) Flow cytometry gating strategy for identification of preNKPs and rNKPs in the bone marrow of WT (Top) and REV-ERB- $\alpha$  KO (Bottom) mice. Percentage of gated population is shown on each flow cytometry graphs (B) Flow cytometry results with percentage of NK cells shown for the identification of mouse NK cells in bone marrow (BM) and spleen of WT and REV-ERB- $\alpha$  KO mice. The results were obtained by using the gating strategy in Figure 3B.

**Figure 11:** (A) Flow cytometry gating strategy for identification of preNKPs and rNKPs in the bone marrow of WT (Top) and REV-ERB- $\alpha$  and REV-ERB- $\beta$  double KO (Bottom) mice. Percentage of gated population is shown on each flow cytometry graphs. (B) Analysis of bone marrow of REV-ERB $\alpha/\beta$  double KO mice. DKO = mice with both REV-ERB $\alpha$  and  $\beta$  genes deleted,  $\alpha$ Het/ $\beta$ Het = mice with only one allele of each REV-ERB gene deleted and  $\beta$ KO = mice with the REV-ERB  $\beta$  gene deleted. N=2 for each data point. LMPP = lymphoid-myeloid pluripotent progenitor cells, CLP = common lymphoid progenitor cells & NKP = NK cell progenitor cells. The y-axis indicates that these cell numbers are represented as percentage of the total lineage-negative cell population of bone marrow.

## DETAILED DESCRIPTION OF THE INVENTION

### Natural Killer Cells

**[0018]** Natural Killer (NK) cells exhibit the highest level of cytotoxic activity within the immune system. NK cells are similar to B cells and T cells, but lack specific cell surface antigen receptors. Instead, NK cells have activatory and inhibitory receptors that recognise motifs.

**[0019]** NK cells circulate in the blood and the peripheral lymphoid organs such as lymph nodes and spleen. They can become activated by cytokines or upon encountering target cells. The recognition and elimination of target cells is based on balancing between inhibitory and activatory signals. Activatory signals are generated by activatory receptors (NKG2D, NKp46, NKp30) binding to ligands, which can be present not only on cancerous, pathogen-infected and damaged cells, but also on healthy cells. On the other hand, inhibitory signals are generated when inhibitory receptors (KIR, CD94/NKG2A) on NK cells bind to Major Histocompatibility Complex (MHC) Class I molecules that are normally present on all healthy cells. MHC Class I molecules on target cells are absent or greatly downregulated, making them ideal NK cell targets. This allowed NK cells to distinguish between target and healthy cells. In order for NK cells to recognise and kill target cells, overall activatory signals must be greater than inhibitory



signals.

**[0020]** NK cells recognise and kill cancerous, pathogen-infected and damaged cells without prior sensitisation, making them part of the innate immune response. For example, NK cells provide an early response to virus infection, occurring prior to T cell killing of infected cells. NK cells can kill target cells within minutes. NK cells also secrete cytokines and "weaponise" other parts of the immune system. For example, NK cells promote T cell effector function and enhance antibody-directed cellular cytotoxicity (ADCC).

**[0021]** NK cells are differentiated from haematopoietic stem cells (HSCs) via the pathway set out in Figure 1. In more detail, NK cells develop from HSCs into Common Lymphoid Progenitor (CLP) cells, pre-NK progenitor (pre-NKP) cells, NK progenitor (NKP) cells, immature NK (iNK) cells, mature NK (mNK) cells and finally into conventional NK (cNK) cells, which circulate in the bloodstream. Although this terminology derives from NK cell development in mice, a corresponding pathway occurs in human NK cell development. For example, HSCs develop through multiple stages of precursors (stage 1, 2 and 3), before developing into mature NK cells (stages 4 and 5). For consistency, references HSCs, CLPs, pre-NKPs, NKPs, iNK, mNK, cNK and NK cells are used herein. However, in the context of the present invention, these terms are interchangeable with stages 1 to 5 of the human nomenclature. Below the diagram of the pathway in Figure 1 are the cytokines and transcription factors that are essential for NK cell development. IL-15 is one of the main cytokine required for the development of NK cells. Other extrinsic factors, such as specific stromal cells, are also required for the development and maturation of NK cells. According to the present invention, Hematopoietic Progenitor Cells (HPCs) are a heterogeneous population containing multi-potential progenitors such as HSCs, CLPs and also NKPs. HPCs are referred to as lineage negative cells, as they have not yet committed to a developmental pathway. Accordingly, in the context of the present invention, HSCs, CLP cells and NKP cells are all HPCs and a reference to HPCs is a reference to any of HSCs, CLP cells and/or CLP cells, or any combination thereof, unless explicitly stated to the contrary.

**[0022]** Due to the importance of NK cells in immune response, multiple clinical trials have tested the efficacy of NK cells in adoptive transfer protocols. Typically this is allogeneic transfer, with the NK cells being isolated from a healthy donor and expanded. However, the downregulation of MHC Class I molecules on target cells is partial and the KIR genotype from donors and recipients may be similar. Due to this, NK cells transfused into recipients, even from different individuals may not attach target cells if their KIRs recognise MHC Class I molecules. Therefore, it is crucial that NK cell donors must be screened for their KIR genotype, where the donor must have the appropriate KIR allelic polymorphism to the recipient to allow recognition of target cells for destruction. Moreover, the expanded products were found to have lower clinical success rate than expected, with less ability to kill cancerous or infected cells.

**[0023]** An NK cell may be defined in terms of its marker expression, its function/activity, or a combination thereof. Such definitions are standard in the art and methods are known by which

marker expression and/or NK cell activity may be assessed. Thus, one of skill in the art would readily be able to categorise a cell as an NK cell using standard methodology and definitions.

**[0024]** For example, mNK and cNK cells may be recognised by their expression of the surface markers CD16 (FcγRIII) and/or CD56, typically both CD16 and CD56 in humans, and NK1.1 or NK1.2 in some mice strains. NKp46 is another marker for mNK and cNK cells, and is expressed in humans and several mice strains. Thus, NKp46 may be used as a marker for NK cells either with or without CD16 and/or CD56 (in humans) or with or without NK1.1 or NK1.2 (in mice). Other examples of markers which can be used to identify/define NK cells according to the present invention include Ly49, natural cytotoxicity receptors (NCRs), CD94, NKG2, killer-cell immunoglobulin-like receptors (KIRs), and/or leukocyte inhibitory receptors (ILT or LIR), or any combination thereof, including in combination with CD16 and or CD56 (in humans) or NK1.1/NK1.2 (in mice). In some preferred embodiments mature NK cells according to the invention (i.e. mNK and cNK cells) are CD56<sup>+</sup> and CD45<sup>+</sup>, and may be also be CD16<sup>+</sup>. As used herein, the term mature human NK cell encompasses NK cells that are CD56<sup>bright</sup> (stage 4) and CD56<sup>dim</sup> (stage 5), both of which are CD56<sup>+</sup>. Mature NK cells may also be defined by the absence of markers, such as CD34, and lymphocyte markers CD3 and/or CD19. Thus, mature NK cells of the invention may be CD56<sup>+</sup>, CD45<sup>+</sup>, CD16<sup>+</sup>, CD3<sup>-</sup> and/or CD19<sup>-</sup>, or any combination thereof, such as CD56<sup>+</sup>, CD45<sup>+</sup>, CD16<sup>+</sup>, CD3<sup>-</sup> and CD19<sup>-</sup>.

**[0025]** In addition or alternatively, an NK may be identified by/defined in terms of its activity. For example, an NK cell may be identified/defined by the presence of cytolytic granules within its cytoplasm, by its ability to secrete antimicrobial molecules such as α-defensins, and/or its ability to secrete cytokines such as TNF-α, IL-10, IFN-γ and TGF-β.

**[0026]** Unless otherwise stated herein, a reference to NK cells includes a reference to iNK, mNK and cNK cells. HSCs, CLP cells and NKPs will typically be referred to as such.

### **Expanded NK cell populations**

**[0027]** As disclosed herein, the invention provides methods for generating an expanded population of NK cells (referred to interchangeably herein as an expanded NK cell population or an NK cell population). Any of the disclosure herein in relation to NK cells of the present invention may also be applied to an expanded NK cell population of the invention.

**[0028]** Typically an expanded NK cell population produced by a method of the invention comprises iNK cells, mNK cells and/or cNK cells, or a combination thereof. Said population may comprise HPCs, such as HSCs, CLP cells and/or NKPs, or a combination thereof, although the numbers of such cells is typically low relative to the number of NK cells, as the majority of these HPCs have differentiated into NK cells in the population. Said population may comprise other immune and/or non-immune cells. Again, the number of any such cells is typically low relative to the number of NK cells present in the population.

**[0029]** As a non-limiting example, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more, up to 100% of the cells of an expanded NK cell population

may be NK cells. Typically at least 80%, preferably at least 90%, more preferably at least 95% of the cells of an expanded NK cell population are NK cells.

**[0030]** At least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more, up to 100% of the cells of an expanded NK cell population produced by a method of the invention are mature NK cells (i.e. mNK cells and/or cNK cells). Preferably at least 80%, more preferably at least 90%, and even more preferably at least 95%, even more preferably at least 98% or more of the cells of an expanded NK cell population are mature NK cells.

**[0031]** The number of HPCs (including HSCs, CLP cells and/or NKP) may be less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11 %, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% of the cells of the expanded NK cell population. Typically the number of HPCs (including HSCs, CLP cells and/or NKP) is less than 20%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2% or less of the cells of the expanded NK cell population.

**[0032]** The number of other immune and/or non-immune cells may be less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11 %, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% of the cells of the expanded NK cell population. Typically the number of other immune and/or non-immune cells is less than 20%, preferably less than 10%, more preferably less than 5% of the cells, even more preferably less than 2%, or less of the expanded NK cell population.

**[0033]** As described herein, the expanded NK cell populations made by the methods of the present invention offer several advantages over NK cell populations made by conventional adoptive transfer methods. In particular, the methods of the present invention enable the production of expanded populations with greater number of NK cells compared with conventional methods. Further, a greater proportion of the NK cells in a population of the invention are functional, preferably fully functional, compared with populations obtained by conventional methods, in which a large number of the NK cells are "exhausted".

**[0034]** As used herein, the term "exhausted" in the context of NK cells means that an NK cell or expanded NK cell population has lost at least some of its effector functions, such as cytotoxic function, cytokine production and/or ADCC. Thus, an exhausted NK cell or expanded NK cell population may exhibit impaired survival, impaired cytotoxic function, altered or

impaired cytokine production and/or impaired ADCC. For example, an exhausted NK cell or exhausted NK cell population may exhibit at least a 50% reduction in one of its effector functions. For example, at least a 50% reduction in cytokine secretion, at least a 50% reduction in ADCC and/or at least 50% reduction in cytotoxic activity. These values may be quantified relative to any appropriate control as defined herein. Any appropriate technique can be used to determine effector function, and hence to quantify and reduction therein. Suitable techniques are known in the art. Alternatively and/or in addition, exhausted NK cells may exhibit altered marker expression, such as an increase in the expression of one or more inhibitory receptor (as described herein) and/or a decrease in the expression of one or more activatory receptor (as described herein). In some embodiments, increased expression of NKG2A and/or Tim3 may be used as a marker for NK cell exhaustion. Again, the expression of these markers may be quantified relative to any appropriate control as defined herein.

**[0035]** In contrast, the terms "functional" and "fully functional" in the context of NK cells means that an NK cell or expanded NK cell population has all of the expected effector functions when responding to a given immune challenge. Thus, a (fully) functional NK cell or expanded NK cell population will typically exhibit cytotoxic function, cytokine production and/or ADCC as would be observed *in vivo* when NK cells are activated in response to an immune challenge, and will typically exhibit enhanced survival compared with NK cells produced using conventional methods. Alternatively and/or in addition, (fully) functional NK cells may exhibit altered marker expression, such as an increase in the expression of one or more activatory receptor (as described herein) and/or a decrease in the expression of one or more inhibitory receptor (as described herein). As a non-limiting example, a functional (mature) human NK cell may be CD56<sup>+</sup> and/or CD45<sup>+</sup>, preferably both CD56<sup>+</sup> and CD45<sup>+</sup>.

**[0036]** As a non-limiting example, the cytotoxicity of NK cells can be determined using a degranulation assay in NK cells co-incubated with 'target cells'. A degranulation assay involves analysing the expression of CD107a within the NK cell population. The amount of CD107a correlates with cytokine secretion and NK cell-mediated lysis of target cells. NK cells can also be analysed for the expression of Interferon- $\gamma$  (IFN- $\gamma$ ), which is the main cytokine secreted when functional NK cells are activated. NK cells that are functional should express similar or higher CD107a as well as IFN- $\gamma$  when compared to a control.

**[0037]** Any increase in NK cell number/functionality in an expanded NK cell population made by a method of the present invention may be compared with the NK cell number/function of an NK cell population obtained from a control method as described herein. A control method may be any standard method known in the art for producing NK cell populations. For example, a control method may use conventional adoptive transfer techniques, rather than a method using a REV-ERB inhibitor according to the present invention. NK cells and NK cell populations produced by such control/standard methods may be used as control cells and populations as described herein.

**[0038]** As an expanded NK cell population made by a method of the present invention comprises significantly fewer exhausted NK cells compared to conventionally prepared NK cell

populations, but instead contains a higher proportion of fully functional NK cells, this advantageously allows the use of smaller numbers of cells to treat patients.

**[0039]** As described herein, the methods of the invention produce expanded NK cell populations with a higher proportion of (fully) functional NK cells compared with conventional methods, which produce populations with large numbers of "exhausted" NK cells. Typically, in an expanded NK cell population of the invention at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more, up to 100% of the NK cells of an expanded NK cell population of the invention are (fully) functional. Typically at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98% or more of the NK cells of an expanded NK cell population of the invention are fully functional, according to any definition (e.g. marker and/or effector function definition) herein.

**[0040]** An expanded NK cell population may be produced by any of the methods disclosed herein. Typically an expanded NK cell population is produced by an *ex vivo* method as disclosed herein.

#### **E4bp4**

**[0041]** E4bp4 (also known as Nfil3) is a basic leucine zipper protein transcription factor which is involved in the regulation of IL-3 expression, and is involved in coordinating the circadian clock. The genomic DNA sequence of the human E4bp4 gene is given in SEQ ID NO: 1 (Genbank Accession No. X64318, version X64318.1). As shown in Figure 1, E4bp4 is expressed in CLPs and is critical in the production of NK cells from blood stem cell progenitors. Mice with the E4bp4 gene deleted do not have functional NK cells, but have normal numbers of T and B cells. In contrast, overexpression of E4bp4 in HSCs *in vitro* increases NK cell production. Thus, E4bp4 is a lineage commitment factor, controlling the development of NKPs from HSCs (Figure 1). E4bp4's critical function in NK cells is specific to the early stages of the developmental pathway, as specific ablation of E4bp4 in peripheral mNK cells does not affect NK cell number or response to cytomegalovirus infection. In addition E4bp4 regulates other transcription factors that are essential in NK cell development, such as Id2 and Eomes.

**[0042]** Although IL-7 and IL-15 have been shown to regulate E4bp4 expression, generally very little is known about how either extrinsic or intrinsic stimuli influence E4bp4. Transcription factors such as E4bp4 can be hard to target because of their structure and function. For example, they usually lack enzymatic activity or cofactor binding sites. However, as demonstrated in the Examples herein, the present inventors have found that E4bp4 expression can be increased using a compound which inhibits the activity of REV-ERB. Further, the present inventors have demonstrated that the use of a REV-ERB inhibitor to increase E4bp4 expression results in an increase in NK cell number. Without wishing to be bound by theory, REV-ERB binds to porphyrin heme, and it is this characteristic that is believed to make REV-ERB a druggable target (see below). In sum, the inventors have shown that by targeting REV-

ERB and inhibiting its activity, it is possible to increase E4bp4 expression and hence increase NK cell number. Accordingly, the present invention is concerned with compounds which inhibit the action of REV-ERB, and their use in increasing E4bp4 expression, and hence NK cell number.

#### **Increase in E4bp4 expression**

**[0043]** Accordingly, the present invention provides *ex vivo* methods for producing expanded NK cell populations, and therapeutic methods and applications for increasing NK cell number in a patient in need thereof. As disclosed herein, said methods and applications involve the use of a compound which inhibits the action of REV-ERB. Typically said compounds act by increasing E4bp4 expression.

**[0044]** An increase in E4bp4 expression may be measured relative to a control. Thus, the expression of E4bp4 in a sample of HPCs, an expanded NK cell population or in a sample obtained from a patient to be treated according to the invention may be compared with the expression of E4bp4 in a control. Expression may be quantified in terms of gene and/or protein expression, and may be compared with expression of a control (e.g. housekeeping gene or protein). The actual amount of the E4bp4 gene, mRNA transcript and/or protein, such as the mass, molar amount, concentration or molarity of the E4bp4 gene, mRNA transcript and/or protein, or the number of mRNA molecules per cell in a sample of HPCs, an expanded NK cell population or in a sample obtained from a patient to be treated according to the invention and the control may be assessed and compared with the corresponding value from the control. Alternatively, the expression of the E4bp4 gene and/or protein in a sample of HPCs, an expanded NK cell population or in a sample obtained from a patient to be treated according to the invention may be compared with that of the control without quantifying the mass, molar amount, concentration or molarity of the one or more gene and/or protein.

**[0045]** Typically the control is an equivalent population or sample in which no increase in E4bp4 expression has been effected. As a non-limiting example, in the case where a patient is treated with a compound that inhibits REV-ERB activity in order to increase E4bp4 expression, a suitable control would be a different individual to which the compound has not been administered or the same individual prior to administration of the compound. Conventional methods for the *ex vivo* expansion of NK cells, including known methods may be considered control methods according to the present invention.

**[0046]** In the context of the present invention, a reference to increasing E4bp4 expression may be understood to mean that, the expression of E4bp4 is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200% compared with the control. Typically E4bp4 expression is increased by at least 50%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90% or more compared with the control.

**[0047]** A reference to increasing E4bp4 expression may be understood to mean that, the expression of E4bp4 is increased by at least 1.5-fold, at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold or more relative to a control. Typically E4bp4 gene expression is increased by at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, or more compared with the control. Typically E4bp4 protein expression is increased by at least 2-fold, at least 3-fold, preferably at least 5-fold, more preferably at least 6-fold or more compared with the control.

**[0048]** The expression of the E4bp4 gene and/or protein according to the invention may be determined by quantitative and/or qualitative analysis. Typically, gene expression may be expressed in terms of mRNA levels.

**[0049]** The expression level of the E4bp4 gene and/or protein according to the invention encompasses the mass of the E4bp4 mRNA transcript and/or protein, the molar amount of the E4bp4 gene, mRNA transcript and/or protein, the concentration of the E4bp4 gene and/or protein and the molarity of the E4bp4 gene and/or protein. This expression level may be given in any appropriate units. For example, the concentration of the E4bp4 gene and/or protein may be given in pg/ml, ng/ml or µg/ml.

**[0050]** The expression level of the E4bp4 gene and/or protein according to the invention may be measured directly or indirectly.

**[0051]** The relative expression of the E4bp4 gene and/or protein according to the invention relative to a control may be determined using any appropriate technique. Suitable standard techniques are known in the art, for example Western blotting, enzyme-linked immunosorbent assays (ELISAs) and RT-qPCR.

**[0052]** The expression level of the E4bp4 gene and/or protein may be increased compared with a control for at least 6 hours, at least 12 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 42 hours, at least 48 hours, at least 54 hours, at least 60 hours, at least 72 hours, at least 4 days, at least 5 days, at least 6 days, at least 1 week. Preferably, the expression level of the E4bp4 gene and/or protein is increased for at least 12 to 72 hours. Typically this is assessed relative to the last administration of the compound which inhibits REV-ERB activity.

**[0053]** The expression level of the E4bp4 gene and/or protein may be increased compared with a control for at least one, at least two, at least three, at least four, at least five, at least ten, at least 20, at least 30, at least 40 or more passages of the NK cell precursors in culture. The expression level of the E4bp4 gene and/or protein may be altered indefinitely.

**REV-ERB**

**[0054]** REV-ERB proteins are members of the nuclear receptor family of intracellular transcription factors. The mRNA sequence of the human REV-ERB $\alpha$  gene (Nr1d1) is given in SEQ ID NO: 3 (Genbank Accession No. NM\_021724, version NM\_021724.4). The mRNA sequence of the human REV-ERB $\beta$  gene (Nr1d2) is given in SEQ ID NO: 5 (Genbank Accession No. AB307693, version AB307693.1). REV-ERB regulates the circadian clock, and has also been implicated in the regulation of cartilage breakdown. It has previously been shown that REV-ERB $\alpha$  knock-out mice have decreased number of TH17 cells compared with the corresponding wild-type mouse strain. However, the role of REV-ERB in NK cell development has not previously been investigated.

**[0055]** Control of E4bp4 expression is a complex multi-component mechanism, involving many transcription factors that bind to E4bp4 regulatory regions, of which REV-ERB is just one. The present inventors have demonstrated for the first time that inhibition of REV-ERB activity is sufficient to elicit a significant increase in E4bp4 expression, and that this in turn brings about an expansion of NK cells, resulting in an increase in NK cell number. As demonstrated in the Examples herein, the present inventors have demonstrated for the first time that inhibition of REV-ERB activity can bring about an increase in NK cell number, and that typically the resulting NK cells are (fully) functional as defined herein. The inventors have further demonstrated that the effect of REV-ERB inhibition is mediated in an E4bp4-dependent manner. Without wishing to be bound by theory, it is believed that inhibition of REV-ERB activity results in an increase in E4bp4 expression (E4bp4 expression is normally repressed by REV-ERB), and that the E4bp4 acts to stimulate the production of NK cells (as shown in Figure 1). In particular, the present inventors have demonstrated that the small molecule SR8278 is capable of binding to the porphyrin heme moiety of REV-ERB, resulting in inhibition of REV-ERB activity and an increase in NK cell number

**[0056]** Accordingly, the present invention is concerned with compounds which inhibit the action of REV-ERB, and their use in increasing E4bp4 expression, and hence NK cell number.

**Inhibition of REV-ERB activity**

**[0057]** The present invention relates to the use of compounds to inhibit the action of REV-ERB, i.e. compounds which inhibit REV-ERB activity. REV-ERB activity may be inhibited by any appropriate means. Suitable standard techniques are known in the art. Inhibition may take place via any suitable mechanism, depending for example on the nature (see below) of the compound used, e.g. steric interference in any direct or indirect interaction or inhibition of REV-ERB. In the context of the present invention a REV-ERB inhibitor (interchangeably referred to herein as a REV-ERB antagonist) is any compound which inhibits, decreases, suppresses or ablates the action of REV-ERB, whether in part or completely.



**[0058]** A decrease in REV-ERB activity may be measured relative to a control. Thus, the activity of REV-ERB in a sample of NK precursor or progenitor cells, an expanded NK cell population or in a sample obtained from a patient to be treated according to the invention may be compared with the activity of REV-ERB in a control. Activity may be quantified in any appropriate terms, for example binding of REV-ERB to the E4bp4 gene, or in terms of E4bp4 expression as defined herein. Any appropriate technique or method may be used for quantifying REV-ERB activity. Suitable techniques are known in the art, for example luciferase assays for quantifying expression of a reporter gene.

**[0059]** Typically the control is an equivalent population or sample in which no REV-ERB inhibitory compound has been added, for example a sample obtained from a different individual to which the compound has not been administered, or the same individual the prior to administration of the compound. Conventional methods for the *ex vivo* expansion of NK cells, including known methods may be considered control methods according to the present invention.

**[0060]** In the context of the present invention, a reference to inhibiting REV-ERB activity may be understood to mean that, the activity of REV-ERB is decreased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, up to total (100%) inhibition of REV-ERB activity, as compared with the control. Typically REV-ERB activity is decreased by at least 50%, preferably at least 70%, more preferably at least 80%, more preferably at least 90%, even more preferably at least 95% or more compared with the control.

**[0061]** The activity of REV-ERB may be determined by quantitative and/or qualitative analysis, and may be measured directly or indirectly.

**[0062]** The activity of REV-ERB relative to a control may be determined using any appropriate technique. Suitable standard techniques are known in the art, such as by quantifying E4bp4 expression, and/or luciferase assays.

**[0063]** The activity of REV-ERB may be inhibited compared with a control for at least 6 hours, at least 12 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 42 hours, at least 48 hours, at least 54 hours, at least 60 hours, at least 72 hours, at least 4 days, at least 5 days, at least 6 days, at least 1 week. Preferably, the activity of REV-ERB is decreased for at least 12 to 72 hours. Typically this is assessed relative to the last administration of the compound which inhibits REV-ERB activity.

**[0064]** The activity of REV-ERB may be inhibited compared with a control for at least one, at least two, at least three, at least four, at least five, at least ten, at least 20, at least 30, at least 40 or more passages of the cells (either *in vivo*, or cultured *ex vivo* or *in vitro*). The activity of REV-ERB may be inhibited and/or the expression level of the E4bp4 gene and/or protein may

be altered indefinitely.

**[0065]** In the context of the present invention any reference to inhibiting REV-ERB activity may be understood to mean inhibiting the activity of REV-ERB $\alpha$  and/or REV-ERB $\beta$ . In preferred embodiments, the activity of both REV-ERB $\alpha$  and REV-ERB $\beta$  is inhibited. Thus, the invention relates to compounds which inhibit REV-ERB activity, including compounds which inhibit REV-ERB $\alpha$  activity (i.e. REV-ERB $\alpha$  inhibitors, also referred to as REV-ERB $\alpha$  antagonists) and/or to compounds which inhibit REV-ERB $\beta$  activity (i.e. REV-ERB $\beta$  inhibitors, also referred to as REV-ERB $\beta$  antagonists). In preferred embodiments, the invention relates to compounds which inhibit the activity of both REV-ERB $\alpha$  and REV-ERB $\beta$  (i.e. REV-ERB $\alpha$  and REV-ERB $\beta$  inhibitors, also referred to as REV-ERB $\alpha$  and REV-ERB $\beta$  antagonists).

#### **REB-ERB antagonists/inhibitors**

**[0066]** Compounds of the invention may be specific for REV-ERB. By specific, it will be understood that the compound binds to REV-ERB $\alpha$  and/or REV-ERB $\beta$ , with no significant cross-reactivity to any other molecule, particularly any other protein. For example, modulator that is specific for REV-ERB $\alpha$  and/or REV-ERB $\beta$  will show no significant cross-reactivity with human neutrophil elastase. Cross-reactivity may be assessed by any suitable method. Cross-reactivity of REV-ERB $\alpha$  and/or REV-ERB $\beta$  inhibitor with a molecule other than REV-ERB $\alpha$  and/or REV-ERB $\beta$  may be considered significant if the inhibitor binds to the other molecule at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100% as strongly as it binds to REV-ERB $\alpha$  and/or REV-ERB $\beta$ . An inhibitor that is specific for REV-ERB $\alpha$  and/or REV-ERB $\beta$  may bind to another molecule such as human neutrophil elastase at less than 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25% or 20% the strength that it binds to REV-ERB $\alpha$  and/or REV-ERB $\beta$ . Preferably, the inhibitor binds to the other molecule at less than 20%, less than 15%, less than 10% or less than 5%, less than 2% or less than 1% the strength that it binds to REV-ERB $\alpha$  and/or REV-ERB $\beta$ .

**[0067]** Compounds of the invention may have off-target effects. An off-target effect is activity against a target other than REV-ERB. Typically compounds with off-target effects are encompassed by the present invention if the activity against the non-REV-ERB target is not significant compared with the activity against REV-ERB. Whether an off-target effect is significant may depend on the intended use of the compound. As a non-limiting example, a compound which may exert an off-target effect on the central nervous system would not be significant for a compound used in an *ex vivo* method as disclosed herein, but may be significant (depending on the magnitude of the off-target effect) for an *in vivo* therapeutic indication as disclosed herein. The presence and magnitude of any potential off target effects can be readily assessed using standard methods known in the art.


**[0068]** Any suitable inhibitor may be used according to the invention, for example small molecules, PROTAC reagents, double stranded RNA (dsRNA), small interfering RNA (siRNA),

small hairpin RNA (shRNA), microRNA, antisense (single stranded) RNA, peptides and peptidomimetics, antibodies, aptamers and ribozymes. Preferred inhibitors include small molecules and PROTAC reagents.

### ***Small molecules***


**[0069]** Small molecules may be used to inhibit REV-ERB activity as described herein. As defined herein, small molecules are low molecular weight compounds, typically organic compounds. Typically, a small molecule has a maximum molecule weight of 900 Da, allowing for rapid diffusion across cell membranes. In some embodiments, the maximum molecular weight of a small molecule is 500 Da. Typically a small molecule has a size in the order of 1nm.


**[0070]** According to the present invention, small molecules may be able to exert an inhibitory effect on REV-ERB activity by binding to the porphyrin heme moiety of REV-ERB. Thus in some preferred embodiments, a compound that inhibits the action of REV-ERB according to the present invention is a compound which binds to the porphyrin heme moiety of REV-ERB, and hence inhibits the activity of REV-ERB. Alternatively, the small molecule may act via a different mechanism, for example, by binding to a non-heme portion of REV-ERB. Standard techniques are known in the art for the production of small molecules, which can then readily be tested for REV-ERB inhibitory activity as described herein.



### **Structure of porphyrin heme**

**[0071]** In a preferred embodiment, the invention relates to the small molecule 1,2,3,4-Tetrahydro-2-[[5-(methylthio)-2-thienyl]carbonyl]-3-isoquinolinecarboxylic acid ethyl ester, herein referred to as SR8278 as a REV-ERB inhibitor.






### Structure of SR8278


**[0072]** The invention also encompasses the use of variants of SR8278 which retain the REV-ERB inhibitory function of SR8278.

**[0073]** Any small molecule which exerts an inhibitory effect on REV-ERB activity may be used as a REV-ERB inhibitor according to the present invention. Such small molecule inhibitors may also bind to REV-ERB. Examples of other small molecules which may be used as REV-ERB inhibitors according to the present invention include 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol (also referred to herein as ARN5187), ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine and 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine.



### Structure of ARN5187


**[0074]**






Structure of ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate

[0075]



Structure of 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide


[0076]



Structure of 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol


[0077]





Structure of 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine

[0078]



Structure of 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine

[0079] The invention also encompasses the use of variants of ARN5187, , ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine or 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine which retain the REV-ERB inhibitory function of ARN5187, , ethyl 2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, 4-((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)-N-phenylpiperidine-1-carboxamide, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine or 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amine respectively.

### ***PROTAC reagents***

[0080] Proteolysis targeting chimeras (also referred to as PROTACs or PROTAC reagents) may be used to inhibit REV-ERB activity as described herein. PROTACs are heterobifunctional

small molecules that simultaneously bind a target protein and ubiquitin ligase, enabling ubiquitination and degradation of the target. In more detail, a PROTAC reagent typically comprises a ligand for the target protein (in the case of the present invention, REV-ERB) and a ligand for an E3 ligase recognition domain. Through the use of such a PROTAC, an E3 ligase is recruited to the PROTAC-bound REV-ERB, inducing ubiquitin transfer from the E3 ligase complex to the target protein (in the case of the present invention, REV-ERB). Once the PROTAC has induced a sufficient degree of ubiquitination of the target, it is then recognised and degraded by the proteasome.

**[0081]** As a non-limiting example, a PROTAC reagent may be produced by conjugating a ligand for an E3-ligase to a small molecule inhibitor as described herein (preferably SR8278) via a linker. In a preferred embodiment, a PROTAC reagent comprises a ligand for the E3 RING Cullin ligase von-Hippel Lindau protein (VHL) or cereblon - a part of a CRL4 E3 RING Cullin ligase complex, connected to a small molecule inhibitor of the invention via a linker. In some particularly preferred embodiments, the PROTAC reagent comprises a ligand for the E3 RING Cullin ligase von-Hippel Lindau protein (VHL) connected to SR8278, connected via a linker. In other particularly preferred embodiments, the PROTAC reagent comprises cereblon (a part of a CRL4 E3 RING Cullin ligase complex) and SR8278, connected via a linker.

**[0082]** Because of their mechanism of action, PROTAC reagents simply need any ligand for the target protein. The functional pharmacology of the ligand, in the absence of the linker and E3 ligase ligand, is unimportant. Therefore in some embodiments a REV-ERB inhibitory PROTAC reagent of the present invention may comprise a small molecule REV-ERB agonist as the ligand, such as GSK4112 (1,1-Dimethylethyl N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl]glycinate, SR6452).

### ***Double-stranded RNA***

**[0083]** Double-stranded RNA (dsRNA) molecules may be used to inhibit REV-ERB activity as described herein. dsRNA molecules may be used in RNAi to inhibit REV-ERB activity.

**[0084]** Using known techniques and based on a knowledge of the sequence of REV-ERB, dsRNA molecules can be designed to antagonise REV-ERB by sequence homology-based targeting of the corresponding RNA sequence. Such dsRNAs will typically be small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), or micro-RNAs (miRNAs). The sequence of such dsRNAs will comprise a portion that corresponds with that of a portion of the mRNA encoding REV-ERB. This portion will usually be 100% complementary to the target portion within the mRNA transcribed from the REV-ERB gene, but lower levels of complementarity (e.g. 90% or more or 95% or more) may also be used. Typically the % complementarity is determined over a length of contiguous nucleic acid residues. A dsRNA molecule of the invention may, for example, have at least 80% complementarity to the target portion within the mRNA transcribed from the REV-ERB gene measured over at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or more nucleic acid

residues, up to the dsRNA molecule having at least 80% complementarity the mRNA transcribed from the REV-ERB gene of the invention over the entire length of the dsRNA molecule.

**[0085]** In a preferred embodiment, the dsRNA is a shRNA. ShRNA can be delivered to NK cell precursors by any appropriate means. Suitable techniques are known in the art and include the use of plasmid, viral and bacterial vectors to deliver the shRNA. Typically, the shRNA is delivered using a viral vector delivery system. In a preferred embodiment, the viral vector is a lentiviral vector.

**[0086]** Generally, once the shRNA has been delivered to an NK precursor cell, it is then transcribed in the nucleus and processed. The resulting pre-shRNA is exported from the nucleus and then processed by dicer and loaded into the RNA-induced silencing complex (RISC). The sense (passenger) strand is degraded. The antisense (guide) strand directs RISC to mRNA that has a complementary sequence. In the case of perfect complementarity, RISC cleaves the mRNA. In the case of imperfect complementarity, RISC represses translation of the mRNA. In both of these cases, the shRNA leads to target gene silencing.

**[0087]** A variant sequence may have at least 80% sequence identity to an shRNA sequence of the invention, measured over any appropriate length of sequence. Typically the % sequence identity is determined over a length of contiguous nucleic acid or amino acid residues. A variant sequence of the invention may, for example, have at least 80% sequence identity to a sequence of the invention measured over at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or more nucleic acid or amino acid residues.

**[0088]** For example, a variant shRNA molecule of the invention may have at least 80% sequence identity with an shRNA molecule of the invention measured over at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more nucleic acid residues, up to the variant shRNA molecule having at least 80% sequence identity with the shRNA molecule of the invention over the entire length of the variant shRNA molecule.

### ***Antisense RNA***

**[0089]** Single-stranded DNA (ssDNA) molecules, also known as antisense RNA, may be used to inhibit REV-ERB activity as described herein.

**[0090]** Using known techniques and based on a knowledge of the sequence of the REV-ERB gene, antisense RNA molecules can be designed to antagonise the REV-ERB gene by sequence homology-based targeting of the corresponding RNA. The sequence of such antisense will comprise a portion that corresponds with that of a portion of the mRNA transcribed from the REV-ERB gene. This portion will usually be 100% complementary to the target portion within the transcribed mRNA but lower levels of complementarity (e.g. 90% or



more or 95% or more) may also be used.

### ***Aptamers***

**[0091]** Aptamers are generally nucleic acid molecules that bind a specific target molecule. Aptamers can be engineered completely in vitro, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. These characteristics make them particularly useful in pharmaceutical and therapeutic utilities.

**[0092]** As used herein, "aptamer" refers in general to a single or double stranded oligonucleotide or a mixture of such oligonucleotides, wherein the oligonucleotide or mixture is capable of binding specifically to a target. Oligonucleotide aptamers will be discussed here, but the skilled reader will appreciate that other aptamers having equivalent binding characteristics can also be used, such as peptide aptamers.

**[0093]** In general, aptamers may comprise oligonucleotides that are at least 5, at least 10 or at least 15 nucleotides in length. Aptamers may comprise sequences that are up to 40, up to 60 or up to 100 or more nucleotides in length. For example, aptamers may be from 5 to 100 nucleotides, from 10 to 40 nucleotides, or from 15 to 40 nucleotides in length. Where possible, aptamers of shorter length are preferred as these will often lead to less interference by other molecules or materials.

**[0094]** Aptamers may be generated using routine methods such as the Systematic Evolution of Ligands by Exponential enrichment (SELEX) procedure. SELEX is a method for the in vitro evolution of nucleic acid molecules with highly specific binding to target molecules. It is described in, for example, US 5,654, 151, US 5,503,978, US 5,567,588 and WO 96/38579.

**[0095]** The SELEX method involves the selection of nucleic acid aptamers and in particular single stranded nucleic acids capable of binding to a desired target, from a collection of oligonucleotides. A collection of single- stranded nucleic acids (e.g., DNA, RNA, or variants thereof) is contacted with a target, under conditions favourable for binding, those nucleic acids which are bound to targets in the mixture are separated from those which do not bind, the nucleic acid-target complexes are dissociated, those nucleic acids which had bound to the target are amplified to yield a collection or library which is enriched in nucleic acids having the desired binding activity, and then this series of steps is repeated as necessary to produce a library of nucleic acids (aptamers) having specific binding affinity for the relevant target.

### ***Peptidomimetics***

**[0096]** Peptidomimetics are compounds which mimic a natural peptide or protein with the

ability to interact with the biological target and produce the same biological effect. Peptidomimetics may have advantages over peptides in terms of stability and bioavailability associated with a natural peptide. Peptidomimetics can have main- or side-chain modifications of the parent peptide designed for biological function. Examples of classes of peptidomimetics include, but are not limited to, peptoids and  $\beta$ -peptides, as well as peptides incorporating D-amino acids.

### ***Antibodies***

**[0097]** Antibodies may be used to inhibit REV-ERB activity as described herein.

**[0098]** As used herein, the term antibody encompasses the use of a monoclonal antibody or polyclonal antibody, as well as the antigen-binding fragments of a monoclonal or polyclonal antibody, or a peptide which binds to REV-ERB with specificity. The antibody may be a Fab, F(ab')<sub>2</sub>, Fv, scFv, Fd or dAb.

### ***Variant Sequences***

**[0099]** A sequence identity of at least 80% includes at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and 100% sequence identity (to each and every sequence presented herein and/ or to each and every SEQ ID NO presented herein).

**[0100]** Any of a variety of sequence alignment methods can be used to determine percent identity, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art. Global methods align sequences from the beginning to the end of the molecule and determine the best alignment by adding up scores of individual residue pairs and by imposing gap penalties. Non-limiting methods include, e.g., CLUSTAL W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, 22 (22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement, see, e.g., Osamu Gotoh, Significant Improvement in Accuracy of Multiple Protein Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. Mol. Biol. 823-838 (1996). Local methods align sequences by identifying one or more conserved motifs shared by all of the input sequences. Non-limiting methods include, e.g., Match-box, see, e.g., Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501-509 (1992); Gibbs sampling, see, e.g., C. E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262 (5131) Science 208-214 (1993); Align-M, see, e.g., Ivo Van Walle et al., Align-M - A New Algorithm for

Multiple Alignment of Highly Divergent Sequences, 20 (9) Bioinformatics:1428-1435 (2004). Thus, percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-16, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-19, 1992.

**[0101]** Variants of the specific sequences provided above may alternatively be defined by reciting the number of nucleotides or amino acids that differ between the variant sequences and the specific reference sequences provided above. Thus, in one embodiment, the sequence may comprise (or consist of) a nucleotide sequence that differs from the specific sequences provided above at no more than 5, no more than 4, no more than 3, no more than 2 nucleotide positions, for example at no more than 1 nucleotide position. Conservative substitutions are preferred.

**[0102]** The variant nucleic acid molecules and peptides of the invention typically still retain the activity of the corresponding molecules of the invention. Thus, for example, the variant shRNA molecules of the invention retain the ability of the corresponding shRNA molecules to inhibit the expression of REV-ERB. The variant shRNA molecules may retain at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, up to and including 100% of the modulatory activity of the shRNA molecules of the invention. This applies equally to any other variants of the inhibitors of the invention.

**[0103]** The compounds of the invention may be labelled (or tagged). Any appropriate label may be used. Suitable labels are known in the art.

#### **Methods of expanding NK cells**

**[0104]** The present invention relates to an *ex vivo* or *in vitro* method for expanding an NK cell population. *In vivo* methods are also described. Said method comprises containing HPCs with a compound that inhibits the action of REV-ERB (as described herein) and expanding said cells to produce an NK cell population. The methods of the invention allow for the rapid expansion of NK cells, reducing the time needed for their culture, and hence the risk of exhaustion, enhancing the cytotoxicity of the NK cells when transfused into a patient.

**[0105]** When the described method is carried out *in vivo*, said method is a therapeutic method as described herein. All the disclosure herein in relation to therapeutic indications and applications of the invention is applicable to said methods.

**[0106]** Typically the method of the invention is *ex vivo*. Accordingly, the invention provides an *ex vivo* method for expanding an NK cell population comprising the steps of: (a) culturing an NK precursor cell comprising sample obtained from a patient; (b) contacting said sample with a compound that inhibits the action of REV-ERB; and (c) expanding said cells *in vitro* to produce an NK cell population. The compound may be any REV-ERB inhibitory compound of the invention as described herein. Typically said compound increases E4bp4 expression by

decreasing REV-ERB activity as described herein.

**[0107]** The sample comprising HPCs obtained from a patient may be a sample obtained from bone marrow, cord blood and/or peripheral blood. Thus, the sample may be a cord or peripheral blood sample, or a bone marrow sample or biopsy.

**[0108]** According to the present invention, a sample comprising HPCs is any sample from a patient which comprises a sufficient number of HPCs (as described herein), such that an expanded NK cell population can be obtained by contacting said sample with a compound according to the present invention. Typically the sample comprises HSCs. Preferably said sample is enriched for HSCs, such as a cord or peripheral blood sample or a bone marrow sample or biopsy as described herein.

**[0109]** The HPCs may be cultured on or with suitable support/stromal cells or cell layer. Any appropriate stromal cell may be used, including, but not limited to OP9 stromal cells and/or EL08-1D2 stromal cells. Alternatively and/or in addition, the HPCs may be cultured in the presence of cytokines and growth factors associated with the development of cells in the NK cell differentiation pathway, including factors required for HPCs growth and/or factors required for NK cell growth and/or differentiation. Non-limiting examples of such factors include IL-3, IL-7, Flt3L, stem cell factor (SCF) and/or IL-15, or any combination thereof.

**[0110]** In some embodiments, the *ex vivo* method comprises a single stage in which the HPCs in a sample obtained from a patient are cultured, contacted with a compound of the invention and expanded to form an NK cell population, typically under substantially constant culture conditions. Typically this involves incubating the HPCs with factors such as IL-3, IL-7, SCF, Flt3L and/or IL-15, preferably all of these factors. The HPCs are preferably also cultured on or with stromal cells/ cell layer, such as EL08-1D2 stromal cells.

**[0111]** In some embodiments, the *ex vivo* method comprises two stages. The first is a lymphoid production stage, in which the HPCs in a sample obtained from a patient are cultured. Typically this involves incubating the HPCs with cytokines and growth factors associated with lymphoid production, such as Flt3L, IL-7 and/or SCF. This stage may last for at least one, at least two, at least three, at least four, or more days. In some preferred embodiments, this stage lasts for two days.

**[0112]** The second stage of the *ex vivo* method is a stage of NK cell expansion. Typically this involves transferring the cultured HSCs to a suitable stromal (support) cell layer, such as OP9 stromal cells and culturing in cytokines and growth factors associated with NK cell development, such as IL-15. A compound of the invention is typically added during this second stage, and preferably at the start of this second stage. The second stage lasts for the remainder of the *ex vivo* culture period (as defined above). The culture medium may be changed as often as required during this second stage in order to facilitate NK cell expansion.

**[0113]** The HPC comprising sample may be cultured *ex vivo* for at least 5 days, at least 6 days,

at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days or more. Typically said sample is cultured for at least 9 days in order to produce an expanded NK cell population. These culture periods are for the total culture period of the *ex vivo* method, i.e. if there are two stages, these periods are for the total (stage 1 plus stage 2).

**[0114]** The compound of the invention may be added to the sample comprising HPCs within one week, within six days, within five days, within four days, within three days, within two days, within one day of isolating the HPCs in the sample, or on the same day as isolating the NK cell precursors. Typically this is the same day that the sample is obtained from the patient. Preferably the compound of the invention is added to the sample within two days of isolating the HPCs in the sample, even more preferably on day two following isolation of the HPCs.

**[0115]** The method of the invention may further comprise modulating (increasing or decreasing the expression and/or activity of one or more additional gene and/or protein in the HPCs in order to enhance NK cell expansion. This modulation may be elicited by a compound of the invention, including the same compound of the invention as used to inhibit the activity of REV-ERB. Alternatively, one or more additional compounds may be used to modulate the expression and/or activity of the one or more additional gene and/or protein. Said modulation may occur directly or indirectly. Indirect modulation encompasses downstream effects caused by a compound of the invention inhibiting the activity of REV-ERB.

**[0116]** A method of the invention may result in an increase in, the number of NK cells of at least 1.5-fold, at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold or more relative to a control. Typically the number of NK cells is increased by at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, or more compared with the control.

**[0117]** Typically an *ex vivo* method of the present invention involves a final step to purify the expanded NK cell population. This ensures a pure population for therapeutic administration as described herein. Purification of the expanded NK cell population may be by any appropriate means. Standard cell purification methods are known in the art, such as cell sorting, including fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).

### **Therapeutic indications**

**[0118]** Also described is a REV-ERB antagonist for use in a method of therapy by increasing the production of NK cells in a patient.

**[0119]** The REV-ERB antagonist for use in said method of therapy may be any REV-ERB

antagonist as described herein. Typically the REV-ERB antagonist for use in said method increases E4bp4 expression by decreasing REV-ERB activity.

**[0120]** Typically the method of therapy comprises administering a compound which inhibits the action of REV-ERB (as described herein) to a patient or subject.

**[0121]** As used herein, the term "increasing the number of NK cells" and "increasing production of NK cells" can be understood to mean that the described compound elicits a significant increase in the number of NK cells in a patient. This increase in NK cell number may be measured relative to a control (as described herein in the context of increasing E4bp4 expression and inhibiting REV-ERB activity).

**[0122]** A reference to an increase in the number of NK cells and/or increasing NK cell production may be quantified in terms of a fold increase relative to a control. Typically a described compound can increase the number of NK cells, or give rise to an increase in NK cell production, of at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 3 fold or more relative to a control.

**[0123]** Alternatively, a reference to increasing the number of NK cells and/or increasing NK cell production may be understood to mean that, the number of NK cells is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300% or more compared with the control. Typically the number of NK cells is increased by at least 50%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90% or more compared with a control.

**[0124]** An increase in the number of NK cells and/or increase in NK cell production may be defined in terms of the absolute number of NK cells in a sample or patient, such as the percentage of NK cells, for example the percentage of NK cells in the circulating lymphocyte population. For example, a compound as described may cause an increase in NK number, resulting in a percentage of NK cells of at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80% or more.

**[0125]** The number of NK cells may be determined by quantitative and/or qualitative analysis, and may be measured directly or indirectly. The number of NK cells relative to a control may be determined using any appropriate technique. Suitable standard techniques, such as flow cytometry, FACS and MACS, are known in the art.

**[0126]** The number of NK cells may be increased compared with a control for at least 6 hours, at least 12 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 42 hours, at least 48 hours, at least 54 hours, at least 60 hours, at least 72 hours, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month or

more. Typically this is assessed relative to the last administration of the compound which inhibits REV-ERB activity.

**[0127]** The number of NK cells may be quantified in terms of the total number of NK cells in a sample from a patient or culture sample (from an *ex vivo* method of the invention).

**[0128]** In the context of the therapeutic uses and methods as described, a "subject" or "patient" (these terms are used interchangeably herein) is any animal patient that would benefit from an increase in the number of NK cells. Typical animal patients are mammals, such as primates. Preferably the patient is a human.

**[0129]** Thus, described herein is a method of treatment by increasing the number of NK cells in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound which inhibits the action of REV-ERB (as described herein).

**[0130]** Additionally, described herein is the use of a compound which inhibits the action of REV-ERB in the manufacture of a medicament. Said medicament increases the number of NK cells in a patient.

**[0131]** Said therapeutic use or method may comprise administering a therapeutically effective amount of a compound as described, either alone or in combination with other therapeutic agents, to a subject.

**[0132]** As used herein, the term "treatment" or "treating" embraces therapeutic or preventative/prophylactic measures.

**[0133]** The compounds as described may also be used as a preventative therapy. As used herein, the term "preventing" includes preventing the onset of symptoms associated with a disease or disorder that may be treated by increasing NK cell number and/or reducing the severity or intensity of said symptoms. The term "preventing" includes inducing or providing protective immunity against such diseases or disorders, particularly infectious diseases as described herein. Immunity may be quantified using any appropriate technique, examples of which are known in the art.

**[0134]** A compound as described may be administered to a patient already having a disease or disorder which may be treated by increasing NK cell number. For example, the patient may be suspected of having an infectious disease or cancer as described herein, and may or may not be showing symptoms of said disease or disorder. When administered to such a patient, a compound of the invention can cure, delay, reduce the severity of, or ameliorate one or more symptoms, and/or prolong the survival of a subject beyond that expected in the absence of such treatment.

**[0135]** Alternatively, a compound as described may be administered to a patient who may ultimately be infected with a particular infectious disease, or develop a disease or disorder as

described herein, in order to cure, delay, reduce the severity of, or ameliorate one or more symptoms, and/or prolong the survival of a subject beyond that expected in the absence of such treatment, or, in the case of infectious diseases help prevent that patient from transmitting said disease.

**[0136]** The treatments and preventative therapies as described are applicable to a variety of different subjects of different ages. In the context of humans, the therapies are applicable to children (e.g. infants, children under 5 years old, older children or teenagers) and adults. In the context of other animal subjects (e.g. mammals such as primates), the therapies are applicable to immature subjects and mature/adult subjects.

**[0137]** The present disclosure relates to the treatment of any disease or disorder which may be beneficially treated with by increasing the number of NK cells in a patient. Such diseases and disorders include cancer, infectious diseases (acute and chronic), autoimmune diseases and diseases or disorders related to female infertility or pregnancy. Infectious diseases that may be treated according to the present invention include viral infection, and infection by other pathogens, including bacteria, protists, fungal, or helminth pathogens. Typically said pathogens are intracellular pathogens which have at least one intracellular phase in their life cycle. Infections of particular interest include viral infections, and zoonotic infections that are of particular importance from a public health perspective. Cancers that may be treated according to the present disclosure include bladder cancer, blood cancers, leukaemia, bone cancers, bowel cancer, brain tumours, breast cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer and uterine cancer. Autoimmune diseases that may be treated according to the present invention include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and obesity-induced insulin resistance. As used herein, the term diseases or disorders related to female infertility or pregnancy includes, but is not limited to, fetal growth restriction, preterm labour, defects in uterine vascular remodelling and preeclampsia.

**[0138]** The compounds as described may be used in combination with one or more additional therapeutic agents or treatments, which typically may be selected from a conventional treatment for the disease or disorder to be treated. As a non-limiting example, if a compound of the invention is for use in the treatment of a cancer, such as lung cancer, then said compound may be used in combination with conventional treatments for lung cancer, such as radiotherapy, chemotherapy or surgery. When used in combination with one or more additional therapeutic agent or treatment, a compound as described may be administered before, simultaneously with, or after the administration of the one or more additional therapeutic agent or treatment.

**[0139]** A compound as described may preferably be for use in combination with antibody-mediated immunotherapy. Antibody-mediated immunotherapy involves the administration of antibodies to a patient to target disease-specific antigens. Such antibodies could be used to increase the specificity and killing activity of NK cells, which express receptors for the  $F_C$  regions of IgG antibodies. Activation of these  $F_C$  receptors, leads to NK cell activation, resulting



in cytokine secretion and release of cytotoxic granules by the activated NK cell, causing lysis of the cell expressing the disease antigen. Such combination therapy is particularly preferred for the treatment of cancer (using antibodies to tumour-specific antigens). Any antibody used in immunotherapy may be used in combination with a compound of the invention. Non-limiting examples of such antibodies include anti-CD20 mAbs (non-Hodgkin's lymphoma, chronic lymphocytic lymphoma), anti-ganglioside D2 (anti-GD2) mAbs (neuroblastoma, melanoma), anti-human epidermal growth factor (anti-HER2) mAbs (breast and gastric cancers), anti-epidermal growth factor receptor (anti-EGFR) mAbs (colorectal and head and neck cancer).

**[0140]** Also described is the use of an expanded NK cell population (as described herein) in a therapeutic use or method as described herein. Any and all of the disclosure herein in relation to therapeutic indications of a compound of the invention may apply equally and independently to therapeutic applications of the expanded NK cell populations of the invention. As a non-limiting example, the disclosure includes an expanded NK cell population (as described herein) for use in a method of therapy, for example in the treatment of cancer, an infectious diseases, an autoimmune disease or a disease or disorder related to female infertility or pregnancy. As another non-limiting example, the disclosure includes a method of treatment by increasing the number of NK cells in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an expanded NK cell population.

#### **Pharmaceutical compositions and formulations**

**[0141]** The term "compound" is herein used interchangeably with the terms "therapeutic/prophylactic composition", "formulation" or "medicament".

**[0142]** The compound or expanded NK cell population as defined above can be combined or administered in addition to a pharmaceutically acceptable carrier, diluent and/or excipient. Alternatively or in addition the compound or expanded NK cell population can further be combined with one or more of a salt, excipient, diluent, adjuvant, immunoregulatory agent and/or antimicrobial compound.

**[0143]** Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or with organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

**[0144]** Administration of immunogenic compositions, therapeutic formulations, medicaments and prophylactic formulations is generally by conventional routes e.g. intravenous, subcutaneous, intraperitoneal, or mucosal routes. The administration may be by parenteral injection, for example, a subcutaneous, intradermal or intramuscular injection. For example, formulations comprising antibodies or expanded NK cell populations as described may be

particularly suited to administration intravenously, intramuscularly, intradermally, or subcutaneously. Administration of small molecule REV-ERB inhibitors may be injection, such as intravenously, intramuscularly, intradermally, or subcutaneously, or by oral administration (small molecules with molecule weight of less than 500 Da typically exhibiting oral bioavailability).

**[0145]** Accordingly, immunogenic compositions, therapeutic formulations, medicaments and prophylactic formulations as described may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection may alternatively be prepared. The preparation may also be emulsified, or the peptide encapsulated in liposomes or microcapsules.

**[0146]** The active immunogenic ingredients (such as the compounds or expanded NK cell populations as described ) are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.

**[0147]** Generally, the carrier is a pharmaceutically-acceptable carrier. Non-limiting examples of pharmaceutically acceptable carriers include water, saline, and phosphate-buffered saline. In some embodiments, however, where the composition comprises a compound as described, this may be in lyophilized form, in which case it may include a stabilizer, such as BSA. In some embodiments, it may be desirable to formulate the composition with a preservative, such as thiomersal or sodium azide, to facilitate long term storage.

**[0148]** Examples of additional adjuvants which may be effective include but are not limited to: complete Freund's adjuvant (CFA), Incomplete Freund's adjuvant (IFA), Saponin, a purified extract fraction of Saponin such as Quil A, a derivative of Saponin such as QS-21, lipid particles based on Saponin such as ISCOM/ISCOMATRIX, E. coli heat labile toxin (LT) mutants such as LTK63 and/ or LTK72, aluminium hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryl oxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2 % squalene/ Tween 80 emulsion, the MF59 formulation developed by Novartis, and the AS02, AS01, AS03 and AS04 adjuvant formulations developed by GSK Biologicals (Rixensart, Belgium).

**[0149]** Examples of buffering agents include, but are not limited to, sodium succinate (pH 6.5), and phosphate buffered saline (PBS; pH 6.5 and 7.5).

**[0150]** Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations or formulations suitable for distribution as

aerosols. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%.

**[0151]** Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.

**[0152]** The dosage ranges for administration of the compounds as described are those which produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the compound, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient's condition, contraindications, if any, and the judgement of the attending physician. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation. Similarly, the dose of a compound as described for use in a disclosed method, particularly an *ex vivo* method of the claimed invention, can be readily determined by one of skill in the art, and is any dose that produces the desired increase in NK cell number and/or elicits the desired expansion in NK cells, to produce an expanded NK cell population. As a non-limiting example, doses of SR8278 according to the present invention may give rise to a final concentration of about 2 to about 20  $\mu\text{M}$ , about 2 to about 15  $\mu\text{M}$ , about 5 to about 15  $\mu\text{M}$ , about 5 to about 14  $\mu\text{M}$ , about 4 to about 13  $\mu\text{M}$ , about 5 to about 12  $\mu\text{M}$ , about 5 to about 11  $\mu\text{M}$ , or preferably about 5 to about 10  $\mu\text{M}$ .

**[0153]** Also described is the use of an expanded NK cell population (as described herein) in a pharmaceutical formulation. Any and all of the disclosure herein in relation to formulations of a compound as described may apply equally and independently to therapeutic applications of the expanded NK cell populations .

#### Key to SEQ ID NOs

#### **[0154]**

#### SEQ ID NO: 1 - E4bp4 gene sequence (X64318.1)

```

1  gccctcttct  ttctctctgt  cggcccgaga  gcaggaacac  gataacgaag  gaggcccaac
61  ttcatccaat  aaggagcctg  acggatttat  ccagacggt  agaacaaaag  gaagaatatt
121 gatggatttt  aaaccagagt  ttttaaagag  cttgagaata  cggggaaatt  aatttgttct
181 cctacacaca  tagatagggt  aaggttggtt  ctgatgcagc  tgagaaaaat  gcagaccgtc
241 aaaaaggagc  aggcgtctct  tgatgccagt  agcaatgttg  acaagatgat  ggtccttaat
301 tctgctttta  cggaagtgtc  agaagactcc  acaacagggt  aggacgtgct  tctcagttaa
361 ggaagtgttg  ggaagaacaa  atcttctgca  tgtcggagga  aacgggaatt  cattoctgat
421 gaaaagaaag  atgctatgta  ttgggaaaaa  aggcggaaaa  ataatgaagc  tgccaaaaga
481 tctcgtgaga  agcgtcgact  gaatgacctg  gttttagaga  acaaaactaat  tgcaactggg
541 gaagaaaacg  ccactttaaa  agctgagctg  ctttcactaa  aattaaagtt  tggtttaatt
601 agctccacag  catatgtcca  agagattcag  aaactcagta  attctacagc  tgtgtacttt

661 caagattacc  agacttccaa  atccaatgtg  agttcatttg  tggacgagca  cgaaccctcg
721 atggtgtcaa  gtagttgtat  ttctgtcatt  aaacactctc  cacaaagctc  gctgtccgat
781 atttcagaag  tctcctcaat  aaacacacac  caggagaact  ctatgcagaa  aactctacaa

```

```

701 gccccagaag tgcctccagc agaacacacg caggagagcc ctgtcagggg aagctgcaga
841 agtctctgaaa acaagttcca gattatcaag caagagccga tggattaga gagctacaca
901 agggagccaa gagatgaccg aggtctttac acagcgtcca tctatcaaaa ctatatgggg
961 aattctttct ctgggtactc aactctctcc ccactactgc aagtcacccg atctctccagc
1021 aactccccga gaacgtcggg aactgatgat ggtgtggtag gaaagtcac tcgatggagaa
1081 gacgagcaac aggtcccca gggcccccac cattctccag ttgaactcaa gcatgtgcat
1141 gcaactgtgg ttaaagttcc agaagtgaat tctctgctc tgcacacaaa gctccggatc
1201 aaagccaaag ccatgcagat caaagtagaa gcctttgata atgaatttga ggccacgcaa
1261 aaacttttct cactattga catgacatct aaaagacatt tcgaactcga aaagcatagt
1321 gccccaaagta tgggtacattc ttctcttact cttttctcag tgcaagtga taacattcaa
1381 gattggtctc tcaaatcgga gcactggcat caaaaagaac tgagtggcaa aactcagaat
1441 agtttcaaaa ctggagtgtg tgaatgaaa gacagtggct acaaagtttc tgaccagag
1501 aacttgtatt tgaagcagg gatagcaaac ttatctgcag aggttgtctc actcaagaga
1561 cttatagcca cacaaccaat ctctgcttca gactctgggt aaattactac tgagtaagag
1621 ctgggcattt agaaagatgt catttgcaat agagcagtc attttgtatt atgctgaatt
1681 ttcactggac ctgtgatgtc atttcaactgt gatgtgcaca tgtgtctgt ttggtgtctt
1741 tttgtgcaca gattatgatg aagattagat tgtgttatca ctctgctgt gtatagtcag
1801 atagtcatat gcgtagggt gtatatatta agnttttatt tttgtgttc tattataaag
1861 tgtgtaagtt accagtttca ataaaggatt ggtgacaaac acagaaaaaa aaaaaaaaaa
1921 aaa

```

### SEQ ID NO: 2 - E4bp4 amino acid sequence (X64318.1)

MQLRKMQTVKKEQASLDASSNVDKMMVLNSALTEVSEDSTTGEDVLLSEGSVGKKNSSACRRKREFIPDEKKDAM  
 YWEKRRKNNEAAKRSREKRLNDLVLENKLIALGEENATLKAELLSLKLKFLGISSTAYAQEIQKLSNSTAVYFQ  
 DYQTSKSNVSSFVDEHEFSMVSSSCISVIKHSPQSSLSDVSEVSSVEHTQESSVQGSRCRSPENKFQIIKQEPMEL  
 ESYTREPRDDRGSYTASIYQNYMGNSFSGYSHSPPLLQVNRSSNSPRTSETDDGVVGKSSDGEDEQQVPGPIH  
 SPVELKHVHATVVKVEPNSSALPHKLRIKAKAMQIKVEAFDNEFEATQKLSSPIDMTSKRHFLEKHSAPSMVH  
 SSLTPFSVQVTNIQDWSLKSEHWQKELSGKTQNSFKTGVVEMKDSGYKVS DPENLYLKQGIANLSAEVVSLKRL  
 IATQPIASDSG

### SEQ ID NO: 3 - REV-ERBa gene sequence (NM\_021724.4)

```

1 gggcacgagg cgtccctcgg gatcacatgg tacctgctcc agtgcccggt gccggcccggt
61 aacctctggc tgcctggcgc tgcgcagagc cctctgtccc agggaaaggc tcgggcaaaa
121 ggcggctgag attggcagag tgaatatatta ctgccgaggg aacgtagcag ggcacacgtc
181 tgcctctttt gcgactcggg gccccgtttc tcccacacac ctacttactt cctggttgca
241 acctctcttc ctctgggact ttgtcacccg gagctccaga ttccgccccc cgcagcgtctg
301 cggagccggc aggcagaggg accccgtaca ctgcagagac ccgacccctc ttgctacctt
361 ctaggccagaa ctactgcagg ctgattcccc ctacacactc tctctgctct tcccatgcaa
421 agcagaactc cgttgctcca acgtccaacc cttctgcagg gctgcagtc gccaccccca
481 agaccttgct gcagggtgct tcggatcctg atcgtgagtc ggggggtcca ctcccgcctc
541 ttagccagtg cccagggggc aacagcggcg atcgcaacct ctagtgtgag tcaagggtcca
601 gtttgaatga ccgctctcag ctggtgaaga catgacgacc ctggactcca acaacaacac
661 aggtggcgct atcacctaca ttggtccag tggctcctcc ccaagccgca ccagccctga
721 atccctctat agtgacaact ccaatggcag cttccagtc ctgacccaag gctgtcccac
781 ctacttccca ccaccccca ctggtccct caccacaagc ccggtctgct cctttgggag
841 cattccaccc agcctgagtg atgacggctc ccctctctcc tcatcttct cgtcgtcatc
901 ctctcctccc ttctataatg ggagccccc tgggagtcta caagtggcca tggaggacag
961 cagccgagtg tccccagca agagcaccag caacatcacc aagctgaatg gcatggtgtt
1021 actgtgtaaa gtgtgtgggg acgttgcttc gggcttccac tacggtgtgc acgctgcga
1081 gggtgcaag ggttttttcc gtccgagcat ccagcagaac atccagtaca aaaggtgtct
1141 gaagaatgag aattgctcca tcgtccgcat caatcgcaac cgtgcccagc aatgtcgtt
1201 caagaagtgt ctctctgtgg gcatgtctcg agacgtgtg cgttttgggc gcatcccca
1261 acgagagaag cagcggatgc ttgctgagat gcagagtgc atgaacctgg ccaacaacca

1321 gttgagcagc cagtgcctgc tggagacttc acccaccag caccacccc caggcccat
1381 gggccctcgt ccacccctg ctccggtccc ctacccctg gtgggttct cocagtttc
1441 acaacagctg acgctccca gatccccaag cctgagccc acagtggagg atgtgatctc
1501 ccaggtggcc cgggcccac gagagatctt cacctacgc catgacaagc tgggcagctc
1561 acctggcaac ttcaatgcca accatgcac aggtagccct ccagccacca cccacatcg
1621 ctgggaaaat cagggtgc ccactgccc caatgacaac aacaccttg ctgccagcg
1681 tcataacgag gccctaaatg gtctgcgcca ggtccctcc tctacccc ccaactggc
1741 tcctggccct gcacaccaca gctgccacca gtccaacagc aacgggcacc gtctatgcc
1801 caccacgtg tatgcagccc cagaaggcaa ggcacctgc aacagtccc ggcagggcaa
1861 ctcaaagaat gttctgctgg catgtctat gaacatgtac ccgcatggac gcagtggcg
1921 aacggtgcag gagatctggg aggatttctc catgagcttc acgcccgtg tgcgggaggt

```

```

1981 ggtagagttt gccaaacaca tcccgggctt ccgtgacctt tctcagcatg accaagtcac
2041 cctgcttaag gctggcacct ttgaggtgct gatggtgcgc tttgcttcgt tgttcaacgt
2101 gaaggaccag acagtgatgt tectaagccg caccacctac agcctgcagg agcttggtgc
2161 catgggcatg ggagacctgc tcagtgccat gttcgacttc agcgagaagc tcaactccct
2221 ggcgcttacc gaggaggagc tgggcctctt caccgcggtg gtgcttgtct ctgcagaccg
2281 ctcgggcatg gagaattccg cttcggtgga gcagctccag gagacgtgc tgcgggctct
2341 tcgggctctg gtgctgaaga accggccctt ggagacttcc cgcttcacca agctgctgct
2401 caagctgccg gacctgcgga ccctgaacaa catgcattcc gagaagctgc tgtccttcg
2461 ggtggacgcc cagtgaaccg cccggccggc cttctgccgc tgcccccttg tacagaatcg
2521 aactctgcac ttctctctcc tttaacgagac gaaaaggaaa agcaaacccag aatcttattt
2581 atattgttat aaaatatctc aagatgagcc tctggccccc tgagccttct tgtaaatacc
2641 tgctccctc ccccatcacc gaacttcccc tctccctta tttaaaccac tctgtctccc
2701 ccacaacctt cccctggccc tctgatttgt tctgttcctg tctcaaatcc aatagttcac
2761 agctgagctg gcttcaaaaa aaaaaaaaaa aaa

```

#### SEQ ID NO: 4 - REV-ERBa amino acid sequence (NM\_021724.4)

```

MTTLDSNNNTGGVITYIGSSGSSPSRTSPESLYSDNSNGSFQSLTQGCPTYFPPSPTGSLTQDPAVSFGSIPPSL
SDDGSPSSSSSSSSSSSSSSSYNGSPPGSLQVAMEDSSRVSPSKSTNITKLNGMVLLCKVCGDVASGFHYGVHACE
GCKGFFRRSIQQNIQYKRLKNENCISIVRINRNRCQQCRFKKCLSVGMSRDAVRFGRI PKREKQRM LAEMQSAMN
LANNQLSSQCPLETSPQHPTPGMPGSPPPAPVPSPVLVGFSGFPQQLTPPRSPEPTVEDVISQVARAHREIF
TYAHDKLGSSPGNFNANHASGSPATTPHRWENQGCPPAPNDNNTLAAQRHNEALNGLRQAPSSYPPTWPPGPAH
HSCHQSNNGHRLCPHVVYAPEGKAPANS PROGNSKNVLLACPMNMYPHGRSGRTVQEIWEDFSMSFTPAVREV
VEFAKHIPGFRDLSQHDQVTLKAGTFEVLMVRFASLFNVKDQTMFLSRTTYSLQELGAMGMGDLLSAMFDFSE
KLNLSALTEEELGLFTAVVLVSADRS GMENSASVEQLQETLLRALRALV LKNRPLETSRFTKLLKLPLDLRLNN
MHSEKLLSFRVDAQ

```

#### SEQ ID NO: 5 - REV-ERBβ gene sequence (AB307693.1)

```

1 atggaggtag atgcaggagg tgtgattgcc tatatcagtt cttccagctc agcctcaagc
61 cctgcctctt gtcacagtga gggttctgag aatagtttcc agtcctcctc ctcttctggt
121 ccactctctc caaatagctc taattctgat accaatggta atcccaagaa tggatgatctc
181 gccaatattg aaggcatctt gaagaatgat cgaatagatt gttctatgaa aacaagcaaa
241 tcgagtgcac ctgggatgac aaaaaatcat agtgggtgta caaaatttag tggcatgggt
301 ctactgtgta aagtctgtgg ggatgtggcg tcaggattcc actatggagt tcatgcttgc
361 gaaggctgta agggtttctt tcggagaagt attcaacaaa acatccagta caagaagtgc
421 ctgaagaatg aaaactgttc tataatgaga atgaatagga acagatgtca gcaatgtcgc
481 ttcaaaaagt gtctgtctgt tggaatgtca agagatgctg ttcggtttgg tcgtattcct
541 aagcgtgaaa aacagaggat gctaattgaa atgcaaagtg caatgaagac catgatgaac
601 agccagttca gtggctactt gcaaaatgac acattagtag aacatcatga acagacagcc
661 ttgccagccc aggaacagct gcgacccaag ccccaactgg agcaagaaaa catcaaaagc
721 tcttctcctc catcttctga ttttgcaaag gaagaagtga ttggcatggt gaccagagct
781 cacaaggata cttttatgta taatcaagag cagcaagaaa actcagctga gagcatgcag

841 ccccagagag gagaacggat tcccaagaac atggagcaat ataatttaaa tcatgatcat
901 tgcggcaatg ggcttagcag ccattttccc tgtagtgaga gcagcagca tctcaatgga
961 cagttcaaaag ggaggaaat aatgcattac ccanatggcc atgccattg tattgcaaat
1021 ggacattgta tgaactctc caatgcttat actcaaagag tatgtgatag agttccgata
1081 gatggatttt ctcaaatga gaacaagaat agttacctgt gcaacactgg aggaagaatg
1141 catctgggtt gtccaatgag taagtctcca tatgtggatc ctcataaatc aggacatgaa
1201 atctgggaag aattttcgat gagcttcact ccagcagtga aagaagtggg ggaatttgca
1261 aagcgtattc ctgggttcag agatctctct cagcatgacc aggtcaacct tttaaaggct
1321 gggacttttg aggttttaat ggtacggttc gcatcattat ttgatgcaaa ggaacgtact
1381 gtcacctttt taagtggaaa gaaatatagt gtggatgatt tacactcaat gggagcaggy
1441 gatctgctaa actctatgtt tgaatttagt gagaagctaa atgccctcca acttagtgat
1501 gaagagatga gtttgtttac agctgttgct ctggtatctg cagatcgatc tggaaatagaa
1561 aacgtcaact ctgtggaggc tttgcaggaa actctcattc gtgcactaag gaccttaata
1621 atgaaaaacc atccaaatga ggcctctatt tttaaaaaac tgcttctaaa gttgccagat
1681 cttcgatctt taaacaacat gcactctgag gagctcttgg cttttaaagt tcaccttaa

```

#### SEQ ID NO: 6 - REV-ERBβ amino acid sequence (AB307693.1)

```

MEVNAGGVIAIYISSSSSASPASCHSEGSNSFQSSSSSVSPSPSSSDTNGNPKNGDLANIEGILKNDRIDCS
MKTSKSSAPGMTKNHSGVTKFSGMVLLCKVCGDVASGFHYGVHACEGCKGFFRRSIQQNIQYKRLKNENCISIMR
MNRNRCQQCRFKKCLSVGMSRDAVRFGRI PKREKQRM LIEMQSAMKTMNSQFSGHLQNDTLVEHHEQTALPAQE
OTLRPKPOTRORNTKSSSPSSSDFAKFEVTVGMVTRAHKDTFMYNORFOFNSAFESMOPORGFRTPKNMFROYNTNHDH

```

CGNGLSSHPCSESQQLNGQFKGRNIMHYXPXGHAICIANGHCMNFSNAYTQRVCDRVPIDGFSQENKNSYLCN  
 TGGRMHLVCPMSKSPYVDPHKSGHEIWEEFMSFTPAVKEVVEFAKRIPGFRDLSQHDQVNLLKAGTFEVLVRF  
 ASLFDKERTVTFLSGKKYSVDDLHSMGAGDLLNSMFEFSEKLNALQLSDEEMSLFTAVVLVSADRSIGIENVNSV  
 EALQETLIRALRTLIMKNHPNEASTFKLLKLPDLRSLNMHSEELLAFKVH

SEQ ID NO: 7 - forward primer A for detection of E4bp4 wildtype allele

CTCTGAGCTTGGCTGATGTG

SEQ ID NO: 8 - reverse primer for the detection of E4bp4

GCTTCAAGTCTCCACCAAGC

SEQ ID NO: 9 - primer for the detection of the E4bp4 null allele

CCATGCTCCTGTCTTGATGA

## EXAMPLES

[0155] The invention will be further clarified by the following examples, which are intended to be purely exemplary of the invention and are in no way limiting.

### **Example 1 - REV-ERB $\alpha$ antagonist SR8278 addition increases percentage NK cell production**

[0156] Initially, a total of seven compounds (SR8278, Remodelin, GSK343, UNC0638, HKMT-1-005, SGC0946 and (R)-PFI-2) at 5, 10, and 20  $\mu$ M were screened along with D4476 as a positive control. GSK343, UNC0638, HKMT-1-005, SGC0946 and (R)-PFI-2 are methyltransferase inhibitors. Methyltransferase inhibitors were tested based on the effect of EZH2 inhibitor.

[0157] Lineage negative cells are enriched for Hematopoietic Progenitor Cells (HPCs). HPCs were isolated and cultured for a total of 9 days and the drugs added on Day 2 (Figure 2). Cells were harvested on Day 9 and analysed using flow cytometry to determine the number of NK1.1<sup>+</sup> CD3<sup>-</sup> cells (Figure 2). NK1.1<sup>+</sup> and CD3<sup>-</sup> are two cell surface markers that can define mouse NK cells. OP9 stromal cells were readily excluded from the analysis, as the OP9 stromal cells used were GFP positive (Figure 3B). Flow cytometry data were analysed as the fold increase, relative to the 'No drug' or untreated control in each experiment. This is because the absolute percentage of NK cell production varies between experiments.

[0158] Out of the seven new compounds tested, only 2 compounds showed a significant increase in NK cell production (Figure 3A), where others did not (data not shown). The addition of 20  $\mu$ M D4476 as well as 5  $\mu$ M Remodelin showed a significant increase but not as striking as 10  $\mu$ M SR8278 (Figure 3A and 3C). When 10  $\mu$ M SR8278 was added, the NK cell production increased over 2.4 fold when compared to the 'No drug' control (Figure 3A and 3C). However

at 20  $\mu$ M SR8278, the compound was toxic and killed most of the cells, hence there was a reduction in the number of NK cells detected (Figure 4). Further experiments were done using SR8278 at 2, 5, 10 and 20  $\mu$ M to confirm its activity. The results were consistent with the previous screen. 10  $\mu$ M SR8278 showed the highest increase in NK cell production, followed by 5  $\mu$ M (Figure 4). [


#### **Example 2 - Optimisation of time of addition of SR8278**

[0159] The effects of SR8278 were further examined. In particular the best time to add SR8278 to the cell culture was investigated. SR8278 was added on Day 0, 1, 2, 3 and 4 of HPC culture in NK cell-producing conditions. The experiment was done using 5 and 10  $\mu$ M SR8278. At 5  $\mu$ M, the addition of SR8278 showed the greatest effect of NK cell production at Day 0 with over 1.4-fold (Figure 5A and 5B). As expected, the addition of 10  $\mu$ M SR8278 showed higher increase in NK cells production compared to 5  $\mu$ M (Figure 5A and 5B). The increase was significant on Days 0, 1 and 2, at over 1.6-fold (Figure 5A and 5B). However, the addition of SR8278 after Day 2 showed no significant difference relative to the 'No drug' control.

[0160] Even though the addition of SR8278 at Days 0 and 1 showed the greatest increase in the percentage NK cells, the numbers of live cells were remarkably low when compared to the 'No drug' control (Figure 5C). It is possible that when SR8278 was added to enhance E4bp4 expression at Day 0 or Day 1, the cells were not primed to differentiate into CLPs or NKPs. Too high dose or too early addition of SR8278 is not sustainable. From these results, Day 2 is the optimum time to add SR8278 to the HPC culture, providing maximal NK cell productions, as well as preserving high live cells counts.

#### **Example 3 - Administration of the REV-ERB agonist, GSK4112, has the opposite effect to SR8278**

[0161] It is predicted that the effect of SR8278 in the increase of NK cells resulted from the inhibition of REVERB, which normally inhibits E4bp4 expression. Therefore, the REV-ERB agonist, GSK4112, was tested to see whether it would lead to a decrease in NK cell production. HPC culture plus the addition of GSK4112 was performed exactly as previously shown in Figure 3.



**Structure of GSK4112 (1,1-Dimethylethyl N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate, SR6452)**

**[0162]** As predicted, NK cell production was reduced by nearly 50%, when GSK4112 was administered (Figure 6). This supports that regulation of REV-ERB results in the control of NK cell development via modulation of E4bp4 expression and that GSK4112 and SR8278 act in this pathway involving REV-ERB- $\alpha$  and E4bp4.

**Example 4 - SR8278 acts on NK cells via E4bp4**

**[0163]** Following the experiment with GSK4112, it was predicted that SR8278 acts through the pathway involving REV-ERB and E4bp4. To confirm whether SR8278 requires E4bp4 to increase NK cell production, SR8278 was tested on HPCs isolated from wild type (WT) (E4bp4<sup>+/+</sup>), E4bp4 knockout (KO) (E4bp4<sup>-/-</sup>) and heterozygous (Het) (E4bp4<sup>+/-</sup>) mice. Cell cultures were performed as previously (Figure 3), where SR8278 was added on Day 2 of the culture and NK cell production was measured by flow cytometry.

**[0164]** Unlike the previous Examples where the data were shown in fold difference in relation to the 'No drug' control, these data are shown as actual percentages of NK cells produced. This is because when E4bp4 KO mice were used, the percentage of NK cell in the 'No drug' control was virtually zero as the absence of E4bp4 halts NK cell development (Figure 7C and 7D). The largest significant increase can be seen when 5  $\mu$ M and 10  $\mu$ M SR8278 were added to HPCs in culture isolated from WT mice compared to the 'No drug' control (Figure 7A and 7D). The effects of culture of HPCs from Het mice were similar to WT mice (Figure 7A, 7B and 7D). On the other hand, there was an absent of NK cells in cultures of HPCs from E4bp4 KO mice regardless of SR8278 concentration (Figure 7C and 7D).

**[0165]** These data support the hypothesis that SR8278 acts on the pathway in which E4bp4 is essential. The presence of E4bp4 is mandatory for SR8278 to successfully increase NK cell production. SR8278 can inhibit the activity of REV-ERB, where REV-ERB normally inhibits E4bp4 expression. Therefore, the inhibition of REV-ERB by SR8278 derepresses E4bp4 expression. The activation of E4bp4 results in the promotion of NK cell development and more NK cells produced (Figure 1).

**Example 5 - Addition of SR8278 increases the expression of E4bp4, Id2 and Eomes**

**[0166]** As the data presented in the above Examples indicates that SR8278 likely acts on the pathway with REV-ERB and E4bp4, it was predicted that genes which are under transcriptional control of E4bp4 such as Id2 and Eomes should be upregulated when E4bp4 expression is



upregulated. HPCs isolated from a WT mouse were cultured as previously (Figure 2) but the cells were harvested and analysed using RT-qPCR on Day 3, 4 and 5. The relative expression of the E4bp4, Id2 and Eomes genes was compared to the housekeeping gene, Hprt. At Day 4, E4bp4, Id2 and Eomes expression was higher in SR8278 treated samples when compared to the 'No drug' control (Figure 8). The increase in E4bp4 expression disappeared at Day 5 but the increase of Id2 expression remained (Figure 8B). The upregulation of E4bp4 and its downstream targets happens in a matter of hours and only stays high for a defined period of time.

**[0167]** These data therefore support the conclusion that SR8278 activates expression of the E4bp4 transcription factor gene, since the known downstream targets of E4bp4 (21) were concomitantly upregulated as well.

#### **Example 6 - SR8278 also enhances NK cell development from human CD34<sup>+</sup> cells**

**[0168]** The hypothesis that SR8278 increases NK cells production would not have any potential therapeutic value if it was not also true for human NK cell production. Therefore, the effect of SR8278 on human NK cell production from human HPCs was examined. Human HPCs were obtained as the CD34<sup>+</sup> population purified from umbilical cord blood from collaborators at the Anthony Nolan Research Institute, London. Human NK cell development goes through a similar developmental pathway to mouse NK cell development. By contrast with mouse HPC culture, human CD34<sup>+</sup> cells were cultured straight onto EL08-1D2 stromal cells in the presence of IL-3, IL-7, Flt3L, SCF and IL-15 cytokines for 14 and 16 days before harvesting and analysis by flow cytometry. To try to optimise human NK cell production, 5 or 10  $\mu$ M SR8278 were added on either day 2, 4 or 6 of the culture.

**[0169]** The data showed that human CD34<sup>+</sup> cells were more sensitive to SR8278 than mouse HPCs as addition of 10  $\mu$ M SR8278 was completely toxic to the cells. However, the effect at 5  $\mu$ M SR8278 was not toxic and the addition of 5  $\mu$ M SR8278 on Day 2 showed a clear increase in NK cell number (Figure 9). Data are shown as percentage of NK cell because from Day 14 to Day 16, the number of NK cell increased exponentially from 5% to 20% in the 'No drug' control (Figure 9). Addition of 5  $\mu$ M SR8278 at Day 4 almost tripled the percentage of NK cells when the cells were harvested at Day 14, increasing from 5.53% to 13.7% (Figure 9). On the other hand, the percentage of NK cell doubled when harvested at Day 16, increasing from 21.8% to 44.3% (Figure 9).

#### **Example 7 - E4bp4 may be inhibited by both REV-ERB $\alpha$ and REV-ERB $\beta$**

**[0170]** Previous work has emphasised the action of REV-ERB- $\alpha$  in inhibiting E4bp4 expression, but the role for the REV-ERB homologue REV-ERB- $\beta$  has not been investigated. In the present investigation, it was therefore decided to directly examine the effect of deleting the REV-ERB- $\alpha$

gene on NK cell production. The previous Examples suggest that REV-ERB- $\alpha$  KO mice would enhance E4bp4 expression and hence enhance NK cell development. HPCs extracted from bone marrow as well as splenocytes taken from WT (Rev-erb- $\alpha^{+/+}$ ) and REV-ERB- $\alpha$  KO mice (Rev-erb- $\alpha^{-/-}$ ) were therefore analysed by flow cytometry. If REV-ERB- $\alpha$  is responsible for the regulation of NK cell production, there should be an increased number of NKP and NK cells in the bone marrow and potentially, also the spleen.

**[0171]** However, as shown in Figure 10, in REV-ERB-  $\alpha$  KO mice, the percentage of NK and NKP cells were no different from the WT. These findings suggest that both REV-ERB- $\alpha$  and REV-ERB- $\beta$ , which is a homologue of REV-ERB- $\alpha$  may be inhibiting E4bp4 expression. When REV-ERB- $\alpha$  is missing, REVERB- $\beta$  may compensate for the activity of REV-ERB- $\alpha$ . Supporting this hypothesis, chromatin immunoprecipitate experiments on REV-ERB- $\alpha$  and REV-ERB- $\beta$  have shown that both REV-ERB- $\alpha$  and REV-ERB- $\beta$  bind to the E4bp4 locus at exactly the same regions. Moreover, SR8278 is actually a dual inhibitor, inhibiting both REVERB-a and REV-ERB- $\beta$ . Therefore, the increase in NK cells when SR8278 was administered may result from the inhibition of both REV-ERBs.

**[0172]** This is supported by the data reported in Figure 11A, which demonstrates that mice deficient in both REV-ERB- $\alpha$  and REV-ERB- $\beta$  have a very significant increase in the number of NKP cells. Figure 11B provides further evidence in support of the joint role of REV-ERB- $\alpha$  and REV-ERB- $\beta$ . Figure 11B shows that in mutant mice with both REV-ERB genes deleted (DKO) there is a consistent increase in NKP cells numbers compared to other "control" mice (WT, mice with only one allele of REV-ERB- $\alpha$  and REV-ERB- $\beta$  deleted ( $\alpha$ Het/ $\beta$ Het), and mice with both copies of REV-ERB- $\beta$  deleted ( $\beta$ KO)), whereas other progenitor cells are not affected.

**[0173]** Therefore, the present inventors have provided the first evidence that inhibition of both REV-ERB- $\alpha$  and REV-ERB- $\beta$ , has therapeutic potential to increase NK cell number, and that such inhibition may be achieved using compounds of the invention such as SR8278.

## **Materials and Methods**

### **Mice**

**[0174]** Wild type mice, E4bp4 heterozygous mice (*E4bp4*<sup>+/-</sup>), E4bp4 knockout mice (*E4bp4*<sup>-/-</sup>), REV-ERB- $\alpha$  knockout mice (*Rev-erb- $\alpha$* <sup>-/-</sup>), REV-ERB- $\beta$  knockout mice (*Rev-erb- $\beta$* <sup>-/-</sup> or  $\beta$ KO), REV-ERB- $\alpha$  and  $\beta$  double knockout mice (*Rev-erb- $\alpha$* <sup>-/-</sup>*Rev-erb- $\beta$* <sup>-/-</sup> or DKO) and REV-ERB- $\alpha$  and  $\beta$  heterozygous mice (*Rev-erb- $\alpha$* <sup>+/-</sup> *Rev-erb- $\beta$* <sup>+/-</sup> or  $\alpha$ Het/ $\beta$ Het) were used. All mice were on a C57BL/6 background, between 6 and 12 weeks old and matched for age and gender. Rbpj<sup>flox/flox</sup> mice were on a FVB background. All animal husbandry and experimental procedures were carried out according to UK Home Office regulations and local guidelines. E4bp4 mice were genotyped

with the forward primer 5'CTCTGAGCTTGGCTGATGTG3' (primer A) and reverse primer 5'GCTTCAAGTCTCCACCAAGC3' (primer B) for detection of the wild type allele or 5'CCATGCTCCTGTCTTGATGA3' for detection of the null allele.

### **Cells and cell culture**

**[0175]** OP9-GFP stromal cells were cultured in Iscove's Modified Dulbecco's Media (IMDM) (Sigma Aldrich) supplemented with 20% Fetal Bovine Serum (FBS), and Penicillin/Streptavidin (P/S). For experiments done on 96-well plates, OP9 stromal cells were plated at the concentration of 2000 cells/well and incubated at 37°C, 5% CO<sub>2</sub> for 1 day before the addition of HPCs. For experiments done on 24-well plates, OP9 stromal cells were plated at the concentration of 4000 cells/well and were incubated at 37°C 5% CO<sub>2</sub> for 2 days prior to addition of HPCs. EL08.1D2 stromal cells were cultured in Minimum Essential Medium Eagle - Alpha Modification (Alpha-MEM) supplemented with 50% Myelocult M5300 (Stem Cell Technologies), 7.5% FBS, 50 µM β-Mercaptoethanol, 1 µM Hydrocortisone and 1% P/S (Sigma Aldrich). For human CD34<sup>+</sup> progenitor cell experiments, EL08.1D2 were irradiated at 3000 rads/ 30 Gy and plated in 96-well EmbryoMax Gelatin (Millipore)-coated plates at the concentration of 20,000 cells/well. There were cultured at 32°C, 5% CO<sub>2</sub> overnight, before CD34<sup>+</sup> cells were transferred onto them.

### **Mouse HPC isolation**

**[0176]** Lineage negative HSCs were purified from mouse bone marrow by crushing the leg bones in Phosphate-buffered Saline (PBS) with 2% fetal calf serum (FCS) (STEMCELL Technologies), topped up to 40 ml with magnetic-activated cell sorting (MACS) buffer (PBS, 2 mM EDTA, 0.5% BSA, sterile and filtered) and centrifuged at 800 g for 2 minutes. The cells were resuspended in PE-conjugated cocktail, (20 µl of anti-B220 (RA3-6B2), anti-mouse CD2 (RM2-5, anti-Ter119 (TER119) and anti-NK.1.1 (PK136) and 5 µl of anti-CD11b (M1/70) and anti-GR-1 (RB6-8C5) antibodies (all from Bioscience)) incubated for 5 minutes at 4°C, centrifuged and resuspended in anti-PE microbeads for 15 minutes at 4°C. Cells were washed in MACS buffer and passed through MACS columns. This allowed negative selection of HPCs. Following lineage depletion, 50 µl of the cells was analysed using flow cytometry to check for purity.

### **In vitro development of NK cells from HPCs**

**[0177]** The HPCs were plated and cultured in 24-well plates at a concentration of 5×10<sup>5</sup> HPCs/well in 1 ml of complete cytokine medium (Dulbecco's modified eagle medium (DMEM) (Sigma Aldrich), 10% FCS, 50 µM β-Mercaptoethanol, 10 ng/ml Flt3-ligand (Flt3L) (R&D

Systems), 10 ng/ml IL-7 (R&D Systems), 100 ng/ml stem cell factor (SCF) (R&D Systems) and 1% P/S) for 2 days at 37°C, 5% CO<sub>2</sub>. The HPCs were then transferred onto OP9 cells at 4500 cells/well for 96-well plate experiments and 3×10<sup>4</sup> cells/well for 24-well plate experiments in mouse NK cells differentiation medium (Alpha-MEM (Sigma Aldrich) plus 20% FCS, 1% P/S and 30 ng/ml IL-15). Cells were left in culture at 37°C, 5% CO<sub>2</sub> for 7 days with a change of mouse NK cells differentiation medium at day 3 or 4.

#### **In vitro development of human umbilical cord blood progenitor cells**

[0178] CD34<sup>+</sup> umbilical cord blood progenitor cells were provided by Anthony Nolan Research Institute, University College London. These cells were isolated from whole cord blood and were cryopreserved in liquid nitrogen for storage and transport. Cells were thawed, counted and then plated on EL08.1D2 plates prepared previously at a concentration of 1000 cells/well in human NK cells differentiation medium (Alpha-MEM plus 20% Human AB serum (Invitrogen), 50 µM β-Mercaptoethanol and 1% P/S along with 5 ng/ml human-IL-3 (Peprotech), 20 ng/ml human-IL-7 (Peprotech), 10 ng/ml human-Flt3-L (Peprotech), 20 ng/ml human-SCF (Peprotech) and 10 ng/ml human-IL-15 (Peprotech). Note that human-IL-3 is only needed for the first week of culture. Cells were left in the culture at 37°C, 5% CO<sub>2</sub> for 14 or 16 days with a change of human NK differentiation medium at day 7 and 12.

#### **Flow cytometry**

[0179] Cells to be analysed by flow cytometry were passed through 40 µm cell strainers to remove clumps and washed with PBS buffer, centrifuged at 800 g for 2 minutes and resuspended in 100µl fluorescent activated cell sorting (FACS) buffer (PBS plus 1% BSA) with appropriate fluorochrome conjugated antibodies at a dilution of 1 in 300. Cells were stained with the following antibodies, all of which were anti-mouse and are from eBioscience unless specified: 2B4 (clone m2B4(B6)458.1; BioLegend), CD2 (RM2-5), CD3 (17A2), CD11b (M1/70), CD19 (1D3), CD27 (LG.7F9), CD122 (TM-b1), CD127 (A7R34), B220 (RA3-6B2), ckit (ACK2), Flt3 (A2F10), Gr1 (RB6-8C5), NK1.1 (PK136), Sca1 (D7), Ter119 (TER119), NKp46 (29A1.4) anti-human CD45 (HI30), anti-human CD2 (RPA-2.10) and anti-human CD56 (CMSSB). The lineage cocktail contained B220, CD2, CD11b, Gr1, NK1.1, and Ter119. Cells were stained in the dark at 4°C for 30 minutes and then washed with 2 ml FACS buffer, centrifuged and resuspend in 300 µl FACS buffer plus Propidium Iodide (PI) also at a dilution of 1 in 300. Flow cytometry was performed using LSRFortessa™ cell analyser (Becton Dickinson Bioscience), sorted using FACSaria (Becton Dickinson) as indicated and full data analysis was done using FlowJo Software.

#### **Polymerase chain reaction (PCR)**

**[0180]** Individual PCR reactions contained 200  $\mu$ M dNTPS, 1  $\mu$ M forward primer (Primer A), 1  $\mu$ M reverse primer (Primer B or C) and 0.5 U Taq polymerase. PCR reactions were set to the following conditions: 94°C for 3 minutes (1 cycle); 94°C for 30 seconds, 59°C for 3 seconds, 72°C for 45 seconds (40 cycles); 72°C for 3 minutes (1 cycle); hold at 4°C.

#### **DNA electrophoresis**

**[0181]** DNA electrophoresis was performed using 1% agarose (Sigma) dissolved in TAE buffer plus 500 ng/ml Ethidium Bromide (Sigma). DNA obtained from PCR reactions was analysed by gel electrophoresis was performed at 100 volts for approximately 45 minutes. Gels were imaged using EC3 Imaging System (Ultra Violet Products Ltd).

#### **RNA purification**

**[0182]** RNA was extracted using Qiagen RNeasy Micro Kit according to the manufacture's protocol (Qiagen). Centrifugation was done at 8000 g for 15 seconds and the flow through discarded. Briefly, 350  $\mu$ l of Buffer RLT + 10% (3-Mercaptoethanol were added to the harvested cells. RNA was further precipitated using 300  $\mu$ l of 70% ethanol and transferred to RNeasy MinElute Spin Column and centrifuged. Next, 350  $\mu$ l of buffer RW1 was added to the MinElute Spin Column and centrifuged. This was followed by the addition of 10  $\mu$ l of DNase I (Qiagen) and 70  $\mu$ l Buffer RDD (Qiagen) and left at room temperature for 15 minutes. 350  $\mu$ l of Buffer RW1 was added to wash off DNase I and centrifuged. 500  $\mu$ l of Buffer RPE was then added to the column and centrifuged, followed by the addition of 500  $\mu$ l of 80% ethanol and centrifuged for 2 minutes. Finally, 14  $\mu$ l of RNase-free water was added to elute the RNA and the column was spun for 1 minute at full speed. The concentration of RNA in each sample was measured using Nanodrop, and all samples were diluted to the same working concentration.

#### **Reverse transcription (conversion of RNA into cDNA)**

**[0183]** Reverse transcription was performed using Transcriptor First Strand cDNA Synthesis kit (Roche). Following the manufacturer's protocol, a template-primer mixture for one 20  $\mu$ l reaction was prepared, where all reagents are provided in the kit: RNA (1  $\mu$ g to 5  $\mu$ g), 2  $\mu$ l Random Hexamer Primer, top the reaction up to 13  $\mu$ l with water (PCR-grade). Next, the template-primer mixture was denatured by heating the tube for 10 minutes at 65°C to remove RNA secondary structures. To that template-primer mixture, 4  $\mu$ l of Transcriptor Reverse Transcriptase Reaction Buffer, 0.5  $\mu$ l of Protector RNase Inhibitor, 2  $\mu$ l of Deoxynucleotide Mix and 0.5  $\mu$ l of Transcriptor Reverse Transcriptase was added. The reagents was mixed and placed In a thermal block cycler with the following settings: 25°C for 10 minutes; 55°C for 30 minutes; 85°C for 5 minutes and store at 4°C.

**Quantification of targeted expressed RNA using Realtime qPCR****[0184]**

| Temperature (°C) | Time       |
|------------------|------------|
| 95               | 20 minutes |
| 95               | 3 seconds  |
| 96               | 30 seconds |

**Conditions used for RT-qPCR**

**[0185]** A standard curve was constructed using splenocytes cDNA diluted to 1, 1:10, 1:100, 1:1000 and 1:10000. To the 2 µl of cDNA produced in the previous step, 5 µl Taqman master mix (Applied Biosystem), 0.5 µl of Taqman gene expression assay kit of Hprt, Nfil3, Id2 or Eomes (Applied Biosystem) and 2.5 µl of RNase-free water. The program used is shown in Table 1 and the reaction was run for 47 cycles.

**Statistical analysis**

**[0186]** Statistical analysis was done using Mann-Whitney test in GraphPad Prism 7

**Discussion**

**[0187]** NK cells are lymphocytes that are capable of producing cytokines, influencing other immune cells as well as killing cancerous, pathogen-infected or damaged cells directly. Due to these properties, researchers are interested in boosting the number of NK cells in order to enhance cytotoxicity against cancerous or pathogen-infected cells. NK cells develop from HSCs in the bone marrow and are controlled by a tightly regulated process involving various transcription factors and cytokines. E4bp4 is the most critical gene regulating NK cell development. E4bp4 has a profound effect on NK cell production despite there being only a relatively small increase in E4bp4 mRNA levels during NK cell development. Little is known about any means that exist to control the activity of E4bp4 protein. The ability to control E4bp4 expression would have highly significant implications for the development and production of NK cells.

**[0188]** The present inventions have demonstrated that upon administration of SR8278, the production of NK cells in NK cell production assays increases more than 2-fold. In the assays

conducted, the optimum time to add SR8278 to the HPC culture for *in vitro* NK cell production was at Day 2 and the optimum dose was 10  $\mu$ M.

**[0189]** Since SR8278 is known to inhibit REV-ERB, an agonist of REV-ERB (GSK4112) was then tested and found to have the opposite effect to SR8278, decreasing NK cell production. This underlines the hypothesis that manipulation of the activity of REVERB may effect NK cell production.

**[0190]** The importance of the presence of E4bp4 for SR8278 function was further investigated. HPCs were isolate from WT, E4bp4 KO and Het mice. In the absence of E4bp4 in E4bp4 KO mice, SR8278 was found to have no effect on the production of NK cells. In order for SR8278 to perform its activity in increasing NK cell production, at least one allele of E4bp4 must be present.

**[0191]** As E4bp4 plays a critical role in the action of SR8278 in increasing NK cell production, the expression of genes that are under transcriptional control of E4bp4 such as Id2 and Eomes was tested, and found to be concomitantly upregulated.

**[0192]** The addition of SR8278 was also found to significantly increase human NK cell development from human HPCs cultured *in vitro*.

**[0193]** Previous experiments emphasized the role of REV-ERB- $\alpha$  in inhibiting E4bp4 expression. To investigate the role of REV-ERB- $\beta$ , a stain test on NKP and NK cells were done using WT and REV-ERB- $\alpha$  KO mice. The percentage NK and NKP cells were found to be similar in wild type and REV-ERB- $\alpha$  KO. It is therefore possible that REV-ERB- $\alpha$  is not the only transcription factor that regulates E4bp4, but its homologue, REV-ERB- $\beta$ , may have the same role as well. In the absence of REV-ERB- $\alpha$ , REV-ERB- $\beta$  would compensate for REV-ERB- $\alpha$  activity as they are highly homologous. This is supported by the data reported herein which demonstrate that double REV-ERB- $\alpha$  and REV-ERB- $\beta$  KO mice demonstrate an increase in the number of NKP cells compared with control cells, and even compared with REV-ERB- $\alpha$  KO or REV-ERB- $\alpha^{+/-}$  and REV-ERB- $\beta^{+/-}$  ( $\alpha$ Het/ $\beta$ Het) mice.

**[0194]** Control of E4bp4 expression by extrinsic stimuli has significant implications for the production of human NK cells for use in immunotherapy. The conventional methods for the production of NK cells from various sources (e.g. induced-pluripotent stem cells and umbilical cord blood stem cells) involves the use of cytokines and stromal cells to commit the cells to the NK lineage, but influencing E4bp4 expression could provide a simple strategy to enhance the process. Thus, the manipulation of E4bp4 expression has potential utility in the production of future NK cell immunotherapeutic products, including the direct mobilisation of NK cell production in vivo as immunotherapy.

## SEQUENCE LISTING

[0195]

&lt;110&gt; IMPERIAL INNOVATIONS LIMITED

&lt;120&gt; NATURAL KILLER CELLS

&lt;130&gt; P48707WO

&lt;150&gt; GB 1703476.0

&lt;151&gt; 2017-03-03

&lt;160&gt; 9

&lt;170&gt; PatentIn version 3.5

&lt;210&gt; 1

&lt;211&gt; 1923

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1833)..(1833)

&lt;223&gt; n is a, c, g, or t

&lt;400&gt; 1

|                                                                    |      |
|--------------------------------------------------------------------|------|
| gccccctttct ttctcctcgt cggcccgaga gcaggaacac gataacgaag gaggcccaac | 60   |
| ttcattcaat aaggagcctg acggatttat ccagacgggt agaacaaaag gaagaatatt  | 120  |
| gatggatttt aaaccagagt ttttaaagag cttgagaata cggggaaatt aatttgttct  | 180  |
| cctacacaca tagatagggg aagggtgttt ctgatgcagc tgagaaaaat gcagaccgtc  | 240  |
| aaaaaggagc aggcgtctct tgatgccagt agcaatgtgg acaagatgat ggtccttaat  | 300  |
| tctgctttaa cggaagtgtc agaagactcc acaacagggt aggacgtgct tctcagtgaa  | 360  |
| ggaagtgtgg ggaagaacaa atcttctgca tgtcggagga aacgggaatt cattcctgat  | 420  |
| gaaaagaaag atgctatgta ttgggaaaaa aggcggaaaa ataatgaagc tgccaaaaga  | 480  |
| tctcgtgaga agcgtcgact gaatgacctg gttttagaga acaaactaat tgcactggga  | 540  |
| gaagaaaacg ccactttaaa agctgagctg ctttactaa aattaaagtt tggtttaatt   | 600  |
| agctccacag catatgctca agagattcag aaactcagta attctacagc tgtgtacttt  | 660  |
| caagattacc agacttccaa atccaatgtg agttcatttg tggacgagca cgaaccctcg  | 720  |
| atgggtgcaa gtagttgtat ttctgtcatt aaacactctc cacaagctc gctgtccgat   | 780  |
| gtttcagaag tgtcctcagt agaacacacg caggagagct ctgtgcaggg aagctgcaga  | 840  |
| agtcctgaaa acaagttcca gattatcaag caagagccga tggaattaga gagctacaca  | 900  |
| agggagccaa gagatgaccg aggcctcttac acagcgtcca tctatcaaaa ctatatgggg | 960  |
| aattctttct ctgggtactc aactctccc ccactactgc aagtcaaccg atcctccagc   | 1020 |
| aactccccga gaacgtcgga aactgatgat ggtgtggtag gaaagtcac tcatggagaa   | 1080 |



```

gacgagcaac aggtcccca gggcccatc cattctccag ttgaactcaa gcatgtgcat      1140
gcaactgtgg ttaaagttcc agaagtgaat tcctctgcct tgccacacaa gctccggatc      1200
aaagccaaag ccatgcagat caaagtagaa gcctttgata atgaatttga ggccacgcaa      1260
aaactttcct cacctattga catgacatct aaaagacatt tcgaactcga aaagcatagt      1320
gccccaaagta tggtagattc ttctcttact cctttctcag tgcaagtgc taacattcaa      1380
gattggtctc tcaaatacga gcaactggat caaaaagaac tgagtggcaa aactcagaat      1440
agtttcaaaa ctggagttgt tgaaatgaaa gacagtggct acaaagtttc tgaccagag      1500
aacttgattt tgaagcaggg gatagcaaac ttatctgcag aggttgctc actcaagaga      1560
cttatagcca cacaaccaat ctctgcttca gactctgggt aaattactac tgagtaagag      1620
ctgggcattt agaaagatgt catttgcaat agagcagtcc attttgatt atgctgaatt      1680
ttcactggac ctgtgatgtc atttcactgt gatgtgcaca tgtgtctgt ttggtgtctt      1740
tttgtgcaca gattatgatg aagattagat tgtgttatca ctctgcctgt gtatagtcag      1800
atagtcatat gcgtaaggct gtatatatta agnttttatt ttgttggtc tattataaag      1860
tgtgtaagtt accagtttca ataaaggatt ggtgacaaac acagaaaaaa aaaaaaaaaa      1920
aaa                                                                1923

```

&lt;210&gt; 2

&lt;211&gt; 462

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Gln Leu Arg Lys Met Gln Thr Val Lys Lys Glu Gln Ala Ser Leu
1           5           10           15

```

```

Asp Ala Ser Ser Asn Val Asp Lys Met Met Val Leu Asn Ser Ala Leu
20           25           30

```

```

Thr Glu Val Ser Glu Asp Ser Thr Thr Gly Glu Asp Val Leu Leu Ser
35           40           45

```

```

Glu Gly Ser Val Gly Lys Asn Lys Ser Ser Ala Cys Arg Arg Lys Arg
50           55           60

```

```

Glu Phe Ile Pro Asp Glu Lys Lys Asp Ala Met Tyr Trp Glu Lys Arg
65           70           75           80

```

```

Arg Lys Asn Asn Glu Ala Ala Lys Arg Ser Arg Glu Lys Arg Arg Leu
85           90           95

```

```

Asn Asp Leu Val Leu Glu Asn Lys Leu Ile Ala Leu Gly Glu Glu Asn

```

100

105

110

```

Ala Thr Leu Lys Ala Glu Leu Leu Ser Leu Lys Leu Lys Phe Gly Leu
115           120           125

```

Ile Ser Ser Thr Ala Tyr Ala Gln Glu Ile Gln Lys Leu Ser Asn Ser  
 130 135 140  
 Thr Ala Val Tyr Phe Gln Asp Tyr Gln Thr Ser Lys Ser Asn Val Ser  
 145 150 155 160  
 Ser Phe Val Asp Glu His Glu Pro Ser Met Val Ser Ser Ser Cys Ile  
 165 170 175  
 Ser Val Ile Lys His Ser Pro Gln Ser Ser Leu Ser Asp Val Ser Glu  
 180 185 190  
 Val Ser Ser Val Glu His Thr Gln Glu Ser Ser Val Gln Gly Ser Cys  
 195 200 205  
 Arg Ser Pro Glu Asn Lys Phe Gln Ile Ile Lys Gln Glu Pro Met Glu  
 210 215 220  
 Leu Glu Ser Tyr Thr Arg Glu Pro Arg Asp Asp Arg Gly Ser Tyr Thr  
 225 230 235 240  
 Ala Ser Ile Tyr Gln Asn Tyr Met Gly Asn Ser Phe Ser Gly Tyr Ser  
 245 250 255  
 His Ser Pro Pro Leu Leu Gln Val Asn Arg Ser Ser Ser Asn Ser Pro  
 260 265 270  
 Arg Thr Ser Glu Thr Asp Asp Gly Val Val Gly Lys Ser Ser Asp Gly  
 275 280 285  
 Glu Asp Glu Gln Gln Val Pro Lys Gly Pro Ile His Ser Pro Val Glu  
 290 295 300  
 Leu Lys His Val His Ala Thr Val Val Lys Val Pro Glu Val Asn Ser  
 305 310 315 320  
 Ser Ala Leu Pro His Lys Leu Arg Ile Lys Ala Lys Ala Met Gln Ile  
 325 330 335  
 Lys Val Glu Ala Phe Asp Asn Glu Phe Glu Ala Thr Gln Lys Leu Ser  
 340 345 350  
 Ser Pro Ile Asp Met Thr Ser Lys Arg His Phe Glu Leu Glu Lys His  
 355 360 365  
 Ser Ala Pro Ser Met Val His Ser Ser Leu Thr Pro Phe Ser Val Gln  
 370 375 380  
 Val Thr Asn Ile Gln Asp Trp Ser Leu Lys Ser Glu His Trp His Gln  
 385 390 395 400  
 Lys Glu Leu Ser Gly Lys Thr Gln Asn Ser Phe Lys Thr Gly Val Val  
 405 410 415  
 Glu Met Lys Asp Ser Gly Tyr Lys Val Ser Asp Pro Glu Asn Leu Tyr  
 420 425 430

420                      425                      430  
 Leu Lys Gln Gly Ile Ala Asn Leu Ser Ala Glu Val Val Ser Leu Lys  
           435                                      440                                      445

Arg Leu Ile Ala Thr Gln Pro Ile Ser Ala Ser Asp Ser Gly  
           450                                      455                                      460

<210> 3

<211> 2793

<212> DNA

<213> Homo sapiens

<400> 3

```

gggcacgagg cgctccctgg gatcacatgg tacctgctcc agtgccgcgt gcggcccggg      60
aaccctgggc tgctggcgcc tgcgcagagc cctctgtccc agggaaaggc tcgggcaaaa      120
ggcggctgag attggcagag tgaaatatta ctgccgaggg aacgtagcag ggcacacgtc      180
tcgcctcttt gcgactcggg gccccgtttc tccccatcac ctacttactt cctggttgca      240
acctctcttc ctctgggact tttgcaccgg gagctccaga ttcgccaccc cgcagcgcgtg      300
cggagccggc aggcagaggg accccgtaca ctgcagagac ccgaccctcc ttgctacctt      360
ctagccagaa ctactgcagg ctgattcccc ctacacactc tctctgctct tcccatgcaa      420
agcagaactc cgttgccctc acgtccaacc cttctgcagg gctgcagtcc ggccacccca      480
agaccttgct gcagggtgct tcggatcctg atcgtgagtc gcgggggtcca ctccccgcc      540
ttagccagtg cccagggggg aacagcggcg atcgcaacct ctagtttgag tcaaggtcca      600
gtttgaatga ccgctctcag ctggtgaaga catgacgacc ctggactcca acaacaacac      660
aggtggcgtc atcacctaca ttggctccag tggctcctcc ccaagccgca ccagccctga      720
atccctctat agtgacaact ccaatggcag cttccagtcc ctgacccaag gctgtcccac      780
ctacttccca ccatccccca ctggctccct cacccaagac ccggctcgct cctttgggag      840
cattccaccc agcctgagtg atgacggctc cccttcttcc tcattcttct cgtcgtcatc      900

ctcctcctcc ttctataatg ggagccccc tgggagtcta caagtggcca tggaggacag      960
cagccgagtg tccccagca agagcaccag caacatcacc aagctgaatg gcatggtgtt     1020
actgtgtaaa gtgtgtgggg acgttgccctc gggttccac tacggtgtgc acgcctgcga     1080
gggctgcaag ggctttttcc gtcggagcat ccagcagaac atccagtaca aaaggtgtct     1140
gaagaatgag aattgctcca tcgtccgcat caatcgcaac cgctgccagc aatgtcgctt     1200
caagaagtgt ctctctgtgg gcatgtctcg agacgctgtg cgttttgggc gcatccccaa     1260
acgagagaag cagcggatgc ttgctgagat gcagagtgcc atgaacctgg ccaacaacca     1320
gttgagcagc cagtgcctgc tggagacttc acccaccag caccacccc caggcccat      1380
gggcccctcg ccaccccctg ctccggtccc ctcacccctg gtgggttct cccagtttcc     1440
acaacagctg acgcctccca gatccccaag ccctgagccc acagtggagg atgtgatatc     1500
ccaggtggcc cgggcccata gagagatctt cacctacgcc catgacaagc tgggcagctc     1560
acctggcaac ttcaatgcc aaccatgcac aggtagccct ccagccacca cccacatcg     1620
ctggcccatc cggccctgag cagctggggg cactggggg cagcccttcc ctggggggg     1680

```

```

ctgggaaaat cagggctgcc cacctgcccc caatgacaa aacaccttgg ctgccagcg 1680
tcataacgag gccctaaatg gtctgcgcca ggctccctcc tctaccctc ccacctggcc 1740
tcctggccct gcacaccaca gctgccacca gtccaacagc aacgggcacc gtctatgcc 1800
caccacgtg tatgcagccc cagaaggcaa ggcacctgcc aacagtcccc ggcagggcaa 1860
ctcaaagaat gttctgctgg catgtcctat gaacatgtac ccgcatggac gcagtgggcg 1920
aacggtgcag gagatctggg aggatttctc catgagcttc acgcccgctg tgcgggaggt 1980
ggtagagttt gccaaacaca tcccgggctt cctgacctt tctcagcatg accaagtcac 2040
cctgcttaag gctggcacct ttgaggtgct gatggtgcgc tttgcttcgt tgttcaacgt 2100
gaaggaccag acagtgatgt tcctaagccg caccacctac agcctgcagg agcttggtgc 2160
catgggcatg ggagacctgc tcagtgccat gttcgacttc agcgagaagc tcaactccct 2220
ggcgcttacc gaggaggagc tgggcctctt caccgggtg gtgcttgtct ctgcagaccg 2280
ctcgggcatg gagaattccg cttcggtgga gcagctccag gagacgctgc tgcgggctct 2340
tcgggctctg gtgctgaaga accggccctt ggagacttcc cgcttcacca agctgctgct 2400
caagctgccg gacctgcgga ccctgaacaa catgcattcc gagaagctgc tgtccttccg 2460
ggtaggacgc cagtgaaccg cccggccggc cttctgcgc tgcctccttg tacagaatcg 2520
aactctgcac ttctctctcc ttacgagac gaaaaggaaa agcaaaccag aatcttattt 2580
atattgttat aaaatattcc aagatgagcc tctggccccc tgagccttct tgtaaatacc 2640
tgctccctc ccccatcacc gaacttcccc tctccctta tttaaaccac tctgtctccc 2700
ccacaacct cccctggccc tctgatttgt tctgttctg tctcaaatcc aatagttcac 2760

agctgagctg gcttcaaaaa aaaaaaaaaa aaa 2793

```

&lt;210&gt; 4

&lt;211&gt; 614

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Thr Thr Leu Asp Ser Asn Asn Asn Thr Gly Gly Val Ile Thr Tyr
1          5          10          15

```

```

Ile Gly Ser Ser Gly Ser Ser Pro Ser Arg Thr Ser Pro Glu Ser Leu
20          25          30

```

```

Tyr Ser Asp Asn Ser Asn Gly Ser Phe Gln Ser Leu Thr Gln Gly Cys
35          40          45

```

```

Pro Thr Tyr Phe Pro Pro Ser Pro Thr Gly Ser Leu Thr Gln Asp Pro
50          55          60

```

```

Ala Arg Ser Phe Gly Ser Ile Pro Pro Ser Leu Ser Asp Asp Gly Ser
65          70          75          80

```

```

Pro Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Phe Tyr Asn
85          90          95

```

```

Gly Ser Asp Asp Gly Ser Leu Gly Val Ala Met Gly Asp Ser Ser Asp

```

Gly Ser Pro Pro Gly Ser Leu Gln Val Ala Met Glu Asp Ser Ser Arg  
 100 105 110  
 Val Ser Pro Ser Lys Ser Thr Ser Asn Ile Thr Lys Leu Asn Gly Met  
 115 120 125  
 Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly Phe His Tyr  
 130 135 140  
 Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile  
 145 150 155 160  
 Gln Gln Asn Ile Gln Tyr Lys Arg Cys Leu Lys Asn Glu Asn Cys Ser  
 165 170 175  
 Ile Val Arg Ile Asn Arg Asn Arg Cys Gln Gln Cys Arg Phe Lys Lys  
 180 185 190  
 Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe Gly Arg Ile  
 195 200 205  
 Pro Lys Arg Glu Lys Gln Arg Met Leu Ala Glu Met Gln Ser Ala Met  
 210 215 220  
 Asn Leu Ala Asn Asn Gln Leu Ser Ser Gln Cys Pro Leu Glu Thr Ser  
 225 230 235 240  
 Pro Thr Gln His Pro Thr Pro Gly Pro Met Gly Pro Ser Pro Pro Pro  
 245 250 255  
 Ala Pro Val Pro Ser Pro Leu Val Gly Phe Ser Gln Phe Pro Gln Gln  
 260 265 270  
 Leu Thr Pro Pro Arg Ser Pro Ser Pro Glu Pro Thr Val Glu Asp Val  
 275 280 285  
 Ile Ser Gln Val Ala Arg Ala His Arg Glu Ile Phe Thr Tyr Ala His  
 290 295 300  
 Asp Lys Leu Gly Ser Ser Pro Gly Asn Phe Asn Ala Asn His Ala Ser  
 305 310 315 320  
 Gly Ser Pro Pro Ala Thr Thr Pro His Arg Trp Glu Asn Gln Gly Cys  
 325 330 335  
 Pro Pro Ala Pro Asn Asp Asn Asn Thr Leu Ala Ala Gln Arg His Asn  
 340 345 350  
 Glu Ala Leu Asn Gly Leu Arg Gln Ala Pro Ser Ser Tyr Pro Pro Thr  
 355 360 365  
 Trp Pro Pro Gly Pro Ala His His Ser Cys His Gln Ser Asn Ser Asn  
 370 375 380  
 Gly His Arg Leu Cys Pro Thr His Val Tyr Ala Ala Pro Glu Gly Lys

```

385              390              395              400

Ala Pro Ala Asn Ser Pro Arg Gln Gly Asn Ser Lys Asn Val Leu Leu
              405              410              415

Ala Cys Pro Met Asn Met Tyr Pro His Gly Arg Ser Gly Arg Thr Val
              420              425              430

Gln Glu Ile Trp Glu Asp Phe Ser Met Ser Phe Thr Pro Ala Val Arg
              435              440              445

Glu Val Val Glu Phe Ala Lys His Ile Pro Gly Phe Arg Asp Leu Ser
              450              455              460

Gln His Asp Gln Val Thr Leu Leu Lys Ala Gly Thr Phe Glu Val Leu
465              470              475              480

Met Val Arg Phe Ala Ser Leu Phe Asn Val Lys Asp Gln Thr Val Met
              485              490              495

Phe Leu Ser Arg Thr Thr Tyr Ser Leu Gln Glu Leu Gly Ala Met Gly
              500              505              510

Met Gly Asp Leu Leu Ser Ala Met Phe Asp Phe Ser Glu Lys Leu Asn
              515              520              525

Ser Leu Ala Leu Thr Glu Glu Glu Leu Gly Leu Phe Thr Ala Val Val
530              535              540

Leu Val Ser Ala Asp Arg Ser Gly Met Glu Asn Ser Ala Ser Val Glu
545              550              555              560

Gln Leu Gln Glu Thr Leu Leu Arg Ala Leu Arg Ala Leu Val Leu Lys
              565              570              575

Asn Arg Pro Leu Glu Thr Ser Arg Phe Thr Lys Leu Leu Leu Lys Leu
              580              585              590

Pro Asp Leu Arg Thr Leu Asn Asn Met His Ser Glu Lys Leu Leu Ser
595              600              605

Phe Arg Val Asp Ala Gln
610

```

<210> 5

<211> 1740

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (994)..(994)

<223> n is a, c, g, or t

&lt;400&gt; 5

|                                                                    |      |
|--------------------------------------------------------------------|------|
| atggagggtga atgcaggagg tgtgattgcc tatatcagtt cttccagctc agcctcaagc | 60   |
| cctgcctctt gtcacagtga gggttctgag aatagtttcc agtcctcctc ctcttctgtt  | 120  |
| ccatcttctc caaatagctc taattctgat accaatggta atcccaagaa tggatgatctc | 180  |
| gccaatattg aaggcatctt gaagaatgat cgaatagatt gttctatgaa aacaagcaaa  | 240  |
| togagtgcac ctgggatgac aaaaaatcat agtgggtgtga caaaatttag tggcatgggt | 300  |
| ctactgtgta aagtctgtgg ggatgtggcg tcaggattcc actatggagt tcatgcttgc  | 360  |
| gaaggctgta agggtttctt tcggagaagt attcaacaaa acatccagta caagaagtgc  | 420  |
| ctgaagaatg aaaactgttc tataatgaga atgaatagga acagatgtca gcaatgtcgc  | 480  |
| ttcaaaaagt gtctgtctgt tggaatgtca agagatgctg ttcggtttgg tcgtattcct  | 540  |
| aagcgtgaaa aacagaggat gctaattgaa atgcaaagtg caatgaagac catgatgaac  | 600  |
| agccagttca gtggtcactt gcaaaatgac acattagtag aacatcatga acagacagcc  | 660  |
| ttgccagccc aggaacagct gcgacccaag cccaactgg agcaagaaaa catcaaaagc   | 720  |
| tcttctcctc catcttctga ttttgcaaag gaagaagtga ttggcatggt gaccagagct  | 780  |
| cacaaggata cctttatgta taatcaagag cagcaagaaa actcagctga gagcatgcag  | 840  |
| cccagagag gagaacggat tccaagaac atggagcaat ataatttaaa tcatgatcat    | 900  |
| tgcggcaatg ggcttagcag ccattttccc tgtagtgaga gccagcagca tctcaatgga  | 960  |
| cagttcaaaag ggaggaatat aatgcattac ccnatggcc atgccatttg tattgcaa    | 1020 |
| ggacattgta tgaacttctc caatgcttat actcaaagag tatgtgatag agttccgata  | 1080 |
| gatggatttt ctcagaatga gaacaagaat agttacctgt gcaacactgg aggaagaatg  | 1140 |
| catctggttt gtccaatgag taagtctcca tatgtggatc ctcataaatc aggacatgaa  | 1200 |
| atctgggaag aattttcgat gagcttcact ccagcagtga aagaagtggg ggaatttgca  | 1260 |
| aagcgtatct ctgggttcag agatctctct cagcatgacc aggtcaacct tttaaaggct  | 1320 |
| gggacttttg aggtttta                                                | 1380 |
| gtcacctttt taagtggaaa gaaatatagt gtggatgatt tacactcaat gggagcaggg  | 1440 |
| gatctgctaa actctatgtt tgaatttagt gagaagctaa atgccctcca acttagtgat  | 1500 |
| gaagagatga gttgttttac agctgttgct ctggtatctg cagatcgatc tggaatagaa  | 1560 |
| aacgtcaact ctgtggaggc tttgcaggaa actctcatc gtgcactaag gaccttaata   | 1620 |
| atgaaaaacc atccaaatga ggcctctatt tttaaaaaac tgcttctaaa gttgccagat  | 1680 |
| cttcgatctt taaacaacat gcactctgag gagctcttgg cctttaaagt tcacccttaa  | 1740 |

&lt;210&gt; 6

&lt;211&gt; 578

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (332)..(332)

<223> Xaa can be any naturally occurring amino acid

<400> 6

```

Met Glu Val Asn Ala Gly Gly Val Ile Ala Tyr Ile Ser Ser Ser Ser
1           5           10           15

Ser Ala Ser Ser Pro Ala Ser Cys His Ser Glu Gly Ser Glu Asn Ser
20           25           30

Phe Gln Ser Ser Ser Ser Ser Val Pro Ser Ser Pro Asn Ser Ser Asn
35           40           45

Ser Asp Thr Asn Gly Asn Pro Lys Asn Gly Asp Leu Ala Asn Ile Glu
50           55           60

Gly Ile Leu Lys Asn Asp Arg Ile Asp Cys Ser Met Lys Thr Ser Lys
65           70           75           80

Ser Ser Ala Pro Gly Met Thr Lys Asn His Ser Gly Val Thr Lys Phe
85           90           95

Ser Gly Met Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly
100          105          110

Phe His Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg
115          120          125

Arg Ser Ile Gln Gln Asn Ile Gln Tyr Lys Lys Cys Leu Lys Asn Glu
130          135          140

Asn Cys Ser Ile Met Arg Met Asn Arg Asn Arg Cys Gln Gln Cys Arg
145          150          155          160

Phe Lys Lys Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe
165          170          175

Gly Arg Ile Pro Lys Arg Glu Lys Gln Arg Met Leu Ile Glu Met Gln
180          185          190

Ser Ala Met Lys Thr Met Met Asn Ser Gln Phe Ser Gly His Leu Gln
195          200          205

Asn Asp Thr Leu Val Glu His His Glu Gln Thr Ala Leu Pro Ala Gln
210          215          220

Glu Gln Leu Arg Pro Lys Pro Gln Leu Glu Gln Glu Asn Ile Lys Ser
225          230          235          240

Ser Ser Pro Pro Ser Ser Asp Phe Ala Lys Glu Glu Val Ile Gly Met
245          250          255

Val Thr Arg Ala His Lys Asp Thr Phe Met Tyr Asn Gln Glu Gln Gln
260          265          270

Glu Asn Ser Ala Glu Ser Met Gln Pro Gln Arg Gly Glu Arg Ile Pro

```



|                                                                 |     |         |
|-----------------------------------------------------------------|-----|---------|
| 275                                                             | 280 | 285     |
| Lys Asn Met Glu Gln Tyr Asn Leu Asn His Asp His Cys Gly Asn Gly |     |         |
| 290                                                             | 295 | 300     |
| Leu Ser Ser His Phe Pro Cys Ser Glu Ser Gln Gln His Leu Asn Gly |     |         |
| 305                                                             | 310 | 315 320 |
| Gln Phe Lys Gly Arg Asn Ile Met His Tyr Pro Xaa Gly His Ala Ile |     |         |
|                                                                 | 325 | 330 335 |
| Cys Ile Ala Asn Gly His Cys Met Asn Phe Ser Asn Ala Tyr Thr Gln |     |         |
|                                                                 | 340 | 345 350 |
| Arg Val Cys Asp Arg Val Pro Ile Asp Gly Phe Ser Gln Asn Glu Asn |     |         |
|                                                                 | 355 | 360 365 |
| Lys Asn Ser Tyr Leu Cys Asn Thr Gly Gly Arg Met His Leu Val Cys |     |         |
|                                                                 | 370 | 375 380 |
| Pro Met Ser Lys Ser Pro Tyr Val Asp Pro His Lys Ser Gly His Glu |     |         |
| 385                                                             | 390 | 395 400 |
| Ile Trp Glu Glu Phe Ser Met Ser Phe Thr Pro Ala Val Lys Glu Val |     |         |
|                                                                 | 405 | 410 415 |
| Val Glu Phe Ala Lys Arg Ile Pro Gly Phe Arg Asp Leu Ser Gln His |     |         |
|                                                                 | 420 | 425 430 |
| Asp Gln Val Asn Leu Leu Lys Ala Gly Thr Phe Glu Val Leu Met Val |     |         |
|                                                                 | 435 | 440 445 |
| Arg Phe Ala Ser Leu Phe Asp Ala Lys Glu Arg Thr Val Thr Phe Leu |     |         |
|                                                                 | 450 | 455 460 |
| Ser Gly Lys Lys Tyr Ser Val Asp Asp Leu His Ser Met Gly Ala Gly |     |         |
| 465                                                             | 470 | 475 480 |
| Asp Leu Leu Asn Ser Met Phe Glu Phe Ser Glu Lys Leu Asn Ala Leu |     |         |
|                                                                 | 485 | 490 495 |
| Gln Leu Ser Asp Glu Glu Met Ser Leu Phe Thr Ala Val Val Leu Val |     |         |
|                                                                 | 500 | 505 510 |
| Ser Ala Asp Arg Ser Gly Ile Glu Asn Val Asn Ser Val Glu Ala Leu |     |         |
|                                                                 | 515 | 520 525 |
| Gln Glu Thr Leu Ile Arg Ala Leu Arg Thr Leu Ile Met Lys Asn His |     |         |
|                                                                 | 530 | 535 540 |
| Pro Asn Glu Ala Ser Ile Phe Thr Lys Leu Leu Leu Lys Leu Pro Asp |     |         |
| 545                                                             | 550 | 555 560 |
| Leu Arg Ser Leu Asn Asn Met His Ser Glu Glu Leu Leu Ala Phe Lys |     |         |
|                                                                 | 565 | 570 575 |

Val His

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer A for detection of E4bp4 wildtype allele

<400> 7

ctctgagctt ggctgatgtg 20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer for the detection of E4bp4

<400> 8

gcttcaagtc tcaccaagc 20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for the detection of the E4bp4 null allele

<400> 9

ccatgctcct gtcttgatga 20

## REFERENCES CITED IN THE DESCRIPTION

### Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all

liability in this regard.

#### Patent documents cited in the description

- [US5654A \[0094\]](#)
- [US151A \[0094\]](#)
- [US5503978A \[0094\]](#)
- [US5567588A \[0094\]](#)
- [WO9638579A \[0094\]](#)

#### Non-patent literature cited in the description

- **CLUSTAL W**Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix ChoiceNucleic Acids Research, 1994, vol. 22, 224673-4680 [\[0100\]](#)
- **OSAMU GOTOH**Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural AlignmentsJ. Mol. Biol., 1996, vol. 264, 4823-838 [\[0100\]](#)
- **ERIC DEPIEREUXERNEST FEYTMANSMATCH-BOXA** Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein SequencesCABIOS, 1992, vol. 8, 5501-509 [\[0100\]](#)
- **C. E. LAWRENCE et al.**Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple AlignmentScience, 1993, vol. 262, 5131208-214 [\[0100\]](#)
- **IVO VAN WALLE et al.**Align-M - A New Algorithm for Multiple Alignment of Highly Divergent SequencesBioinformatics, 2004, vol. 20, 91428-1435 [\[0100\]](#)
- **ALTSCHUL et al.**Bull. Math. Bio., 1986, vol. 48, 603-16 [\[0100\]](#)
- **HENIKOFFHENIKOFF**Proc. Natl. Acad. Sci. USA, 1992, vol. 89, 10915-19 [\[0100\]](#)

**Patentkrav**

1. *Ex vivo*-fremgangsmåde til at ekspandere en NK-cellepopulation, omfattende trin med at:

- 5 a) dyrke en hæmatopoietisk progenitorcelle (HPC) omfattende en prøve, der er opnået fra en patient;
- b) at bringe prøven i kontakt med en forbindelse, som inhiberer virkningen af REV-ERB; og
- c) ekspandere cellerne *in vitro* for at fremstille en NK- cellepopulation.

10

2. Fremgangsmåde ifølge krav 1, hvor forbindelsen øger E4bp4-ekspressionen ved at nedsætte REV-ERB-aktivitet.

3. Fremgangsmåde ifølge krav 1 eller 2, hvor forbindelsen nedsætter aktiviteten af

15

- (a) REV-ERB- $\alpha$  og/eller REV-ERB- $\beta$ , fortrinsvis REV-ERB- $\beta$ ; eller
- (b) REV-ERB- $\alpha$  og REV-ERB- $\beta$

4. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor forbindelsen er:

20

- (a) en REV-ERB-antagonist, fortrinsvis en antagonist af REV-ERB- $\alpha$  og REV-ERB- $\beta$ ; og/eller
- (b) udvalgt fra et lille molekyle, et PROTAC-reagens, et dobbeltstrenget RNA (dsRNA), et lille interfererende RNA (siRNA), et lille hårnåle-RNA (shRNA), et mikro-RNA, et antisense-RNA, en aptamer, et antistof, et ribozym, et peptid
- 25 eller et peptidmimetikum, hvor forbindelsen fortrinsvis er et lille molekyle.

25

5. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor forbindelsen er SR8278, ARN5187, ethyl-2-(5-methylfuran-2-carbonyl)-1,2,3,4-tetrahydroisoquinolin-3-carboxylat, 4-((4-chlorobenzyl)((5-nitrothiophen-2-

30

5 yl)methyl)amino)-N-phenylpiperidin-1-carboxamid, 4-(((1-(4-fluorophenyl)cyclopentyl)amino)methyl)-2-((4-methylpiperazin-1-yl)methyl)phenol, 1-(2-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amin eller 1-(4-fluorophenyl)-N-(3-((1-methylpiperidin-4-yl)methyl)benzyl)cyclopentan-1-amin, fortrinsvis SR8278.

10 **6.** Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor prøven af HPC'er er opnået fra knoglemarv, navlestrengsblod og/eller perifert blod.

**7.** Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor forbindelsen tilsættes inden for 2 dage efter isolering af HPC'erne i prøven ifølge krav 1(a).

# DRAWINGS

Figure 1





Figure 2






Figure 3

Figure 3 (continued)






Figure 4




Figure 5

A




Figure 5 (continued)




Figure 5B (continued)




Figure 5 (continued)




Figure 6




Figure 7




Figure 7 (continued)


**D****NK1.1**



Figure 8




Figure 9




Figure 9 (continued)



**C**

Figure 10







Figure 10 (continued)

Figure 11

A






Figure 11 (continued)

**B**